
(
  (S
    (NP
      (NP (NN Sex) (NN hormone) (NN modulation))
      (PP (IN of)
        (NP (NN cell)
          (NP
            (NP (NN growth))
            (CC and)
            (NP (NN apoptosis)))))
      (PP (IN of)
        (NP (DT the) (JJ human) (NN monocytic/macrophage) (NN cell) (NN line))))))

(
  (S
    (NP (NN Abstract))))

(
  (S
    (S
      (NP (NN Sex) (NNS hormones))
      (VP (VBP seem)
        (S
          (VP (TO to)
            (VP (VB modulate)
              (NP (DT the) (JJ immune/inflammatory) (NNS responses))
              (PP (IN by)
                (NP
                  (NP (JJ different) (NNS mechanisms))
                  (PP (IN in)
                    (NP
                      (ADJP
                        (ADJP (JJ female))
                        (CC and)
                        (ADJP (JJ male)))
                      (NP (JJ rheumatoid) (NN arthritis))
                      (NNS patients))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NNS effects))
        (PP
          (PP (IN of)
            (NP (NN 17β-oestradiol)))
          (CC and)
          (PP (IN of)
            (NP (NN testosterone)))))
      (VP (VBD were)
        (VP (VBN tested)
          (PP (IN on)
            (NP
              (NP
                (NP (DT the) (VBN cultured) (JJ human) (NN monocytic/macrophage) (NN cell) (NN line))
                (PRN (-LRB- -LRB-)
                  (NP (NN THP-1))
                  (-RRB- -RRB-)))
              (VP (VBN activated)
                (PP (IN with)
                  (NP (NN IFN-γ))))))
          (SBAR (IN in) (NN order)
            (S
              (VP (TO to)
                (VP (VB investigate)
                  (NP
                    (NP (PRP$ their) (NN role))
                    (PP (IN in)
                      (NP (NN cell)
                        (NP
                          (NP (NN proliferation))
                          (CC and)
                          (NP (NN apoptosis)))))))))))))
    (. .)))

(
  (S
    (S
      (NP (VBN Activated) (JJ human) (NN THP-1) (NNS cells))
      (VP (VBD were)
        (VP (VBN cultured)
          (PP (IN in)
            (NP
              (NP (DT the) (NN presence))
              (PP (IN of)
                (NP
                  (NP (NN 17β-oestradiol))
                  (CC and)
                  (NP (NN testosterone))))))
          (PRN (-LRB- -LRB-)
            (NP
              (NP (JJ final) (NN concentration))
              (, ,)
              (NP (CD 10) (NN nM)))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN evaluation))
        (PP (IN of)
          (NP
            (NP (NNS markers))
            (PP (IN of)
              (NP (NN cell) (NN proliferation))))))
      (VP (VBD included)
        (NP
          (NP (DT the) (JJ NF-κB) (JJ DNA-binding) (NN assay))
          (, ,)
          (NP (DT the) (JJ NF-κB) (NN inhibition) (NN complex))
          (, ,)
          (NP
            (NP (DT the) (VBG proliferating) (NN cell) (JJ nuclear) (NN antigen))
            (NN expression))
          (CC and)
          (NP (DT the) (JJ methyl-tetrazolium) (NN salt) (NN test)))))
    (. .)))

(
  (S
    (S
      (NP (NN Apoptosis))
      (VP (VBD was)
        (VP (VBN detected)
          (PP
            (PP (IN by)
              (NP (DT the) (NN annexin) (NN V-propidium) (NN assay)))
            (CC and)
            (PP (IN by)
              (NP
                (NP (DT the) (VBN cleaved) (NN poly-ADP) (NN ribose) (NN polymerase))
                (NN expression)))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Specific) (NNS methods))
      (VP (VBD included)
        (NP
          (NP (NN flow) (NN analysis) (NN cytometry) (NN scatter) (NN analysis))
          (, ,)
          (NP (NN immunocytochemistry))
          (CC and)
          (NP (NN western) (NN blot) (NN analysis)))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Cell) (NN growth) (NN inhibition))
        (CC and)
        (NP (VBN increased) (NN apoptosis)))
      (VP (VBD were)
        (VP (VBN observed)
          (PP (IN in)
            (NP (JJ testosterone-treated) (NN THP-1) (NNS cells))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP (VBN Increased) (NN poly-ADP) (NN ribose) (JJ polymerase-cleaved) (NN expression))
          (CC and)
          (NP (VBN decreased)
            (NP (JJ proliferating) (NN cell) (JJ nuclear) (NN antigen))
            (NN expression)))
        (, ,)
        (CONJP (RB as) (RB well) (IN as))
        (NP
          (NP
            (NP
              (NP (DT an) (NN increase))
              (PP (IN of)
                (NP (NN IκB-α))))
            (CC and)
            (NP
              (NP (DT a) (NN decrease))
              (PP (IN of)
                (NP (DT the) (JJ IκB-α) (JJ phosphorylated) (NN form)))))
          (PRN (-LRB- -LRB-)
            (NP (NN ser) (CD 32))
            (-RRB- -RRB-)))
        (, ,))
      (VP (VBD were)
        (VP (VBN found)
          (PP (IN in)
            (NP (JJ testosterone-treated) (NN THP-1) (NNS cells))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB However))
      (, ,)
      (NP (DT the) (JJ NF-κB) (NN DNA) (NN binding))
      (VP (VBD was)
        (VP (VBN found)
          (VP (VBN increased)
            (PP (IN in)
              (NP (JJ 17β-oestradiol-treated) (NN THP-1) (NNS cells)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN treatment))
        (PP (IN with)
          (NP
            (NP (NN staurosporine))
            (PRN (-LRB- -LRB-)
              (NP
                (NP (NN enhancer))
                (PP (IN of)
                  (NP (NN apoptosis))))
              (-RRB- -RRB-)))))
      (VP (VBD induced)
        (NP (VBN decreased) (NN NF-κB) (NN DNA) (NN binding))
        (PP
          (PP (IN in)
            (NP (DT all) (NNS conditions)))
          (, ,)
          (CC but)
          (ADVP (RB particularly))
          (PP (IN in)
            (NP (JJ testosterone-treated) (NN THP-1) (NNS cells))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Treatment))
        (PP (IN of)
          (NP (NN THP-1)))
        (PP (IN by)
          (NP (NN sex) (NNS hormones))))
      (VP (VBD was)
        (VP (VBN found)
          (S
            (VP (TO to)
              (VP (VB influence)
                (NP (NN cell)
                  (NP
                    (NP (NN proliferation))
                    (CC and)
                    (NP (NN apoptosis))))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (NNS Androgens))
        (VP (VBD were)
          (VP (VBN found)
            (S
              (VP (TO to)
                (VP (VB increase)
                  (NP (DT the) (NN apoptosis))))))))
      (, ,)
      (CC and)
      (S
        (NP (NNS oestrogens))
        (VP (VBD showed)
          (NP
            (NP (DT a) (JJ protective) (NN trend))
            (PP (IN on)
              (NP
                (NP (NN cell) (NN death))
                (VP
                  (VP (VBN –))
                  (CC both)
                  (VP (VBG acting)
                    (PP (IN as)
                      (NP
                        (NP (NNS modulators))
                        (PP (IN of)
                          (NP (DT the) (JJ NF-κB) (NN complex)))))))))))))
    (. .)))

(
  (S
    (NP (NN Introduction))))

(
  (S
    (S
      (NP
        (ADJP
          (ADJP (JJ Experimental))
          (CC and)
          (ADJP (JJ clinical)))
        (NN evidence))
      (VP
        (VP (VBZ indicates)
          (SBAR (IN that)
            (S
              (NP (JJ immune) (NN reactivity))
              (VP (VBZ is)
                (ADJP
                  (ADJP (JJR greater))
                  (PP (IN in)
                    (NP (NNS females)))
                  (PP (IN than)
                    (PP (IN in)
                      (NP (NNS males)))))))))
        (CC and)
        (VP (VBZ suggests)
          (SBAR (IN that)
            (S
              (NP (JJ gonadal) (NNS steroids))
              (VP (MD may)
                (VP (VB play)
                  (NP (DT an) (JJ important) (NN role))
                  (PP (IN in)
                    (NP
                      (NP (DT the) (NN regulation))
                      (PP (IN of)
                        (NP (DT the) (JJ immune) (NN response) (CD -LSB-1-4) (-RRB- -RSB-))))))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Indeed))
      (, ,)
      (NP
        (NP (JJ many) (NNS cells))
        (PP (IN of)
          (NP (DT the) (JJ immune) (NN system))))
      (VP (VBP have)
        (VP (VBN been)
          (VP (VBN found)
            (S
              (VP (TO to)
                (VP (VB possess)
                  (NP
                    (NP (JJ functional) (NN sex) (NN hormone) (NNS receptors))
                    (, ,)
                    (PP (JJ such) (IN as)
                      (NP
                        (NP (JJ CD8-positive) (NN T) (NNS cells))
                        (, ,)
                        (NP (NN B) (NNS cells))
                        (CC and)
                        (, ,)
                        (ADVP (RB notably))
                        (, ,)
                        (NP (NNS monocytes/macrophages) (CD -LSB-5,6) (-RRB- -RSB-))))))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Therefore))
      (, ,)
      (NP
        (NP (NN 17β-oestradiol))
        (PRN (-LRB- -LRB-)
          (NP (NN E2))
          (-RRB- -RRB-)))
      (VP (VBD was)
        (VP (VBN found)
          (S
            (VP
              (VP (TO to)
                (VP (VB inhibit)
                  (NP (JJ cellular) (NN apoptosis))))
              (, ,)
              (VP (TO to)
                (VP (VB increase)
                  (NP
                    (NP (NN antibody) (NN production))
                    (PP (IN by)
                      (NP (NN B) (NNS cells))))))
              (CC and)
              (VP (TO to)
                (VP (VB exert)
                  (NP (JJ dose-related) (NNS effects))
                  (PP (IN on)
                    (NP (NN T-cell) (NNS functions) (CD -LSB-7) (-RRB- -RSB-))))))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Androgens))
      (VP (VBP seem)
        (S
          (VP (TO to)
            (VP (VB exert)
              (NP
                (NP (NNS effects))
                (ADJP (JJ opposite)
                  (PP (TO to)
                    (NP
                      (NP (DT those))
                      (PP (IN of)
                        (NP (NN E2)))))))
              (PP (IN on)
                (NP (JJ immune) (NN response) (CD -LSB-8)))))
          (-RRB- -RSB-))))
    (. .)))

(
  (S
    (S
      (NP (JJ Clinical) (NN epidemiology))
      (ADVP (RB clearly))
      (VP (VBZ confirms)
        (NP
          (NP (DT a) (JJR higher) (NN prevalence))
          (PP (IN of)
            (NP (JJ autoimmune) (NNS diseases)))
          (PP (IN in)
            (NP (JJ female) (NNS subjects))))
        (SBAR
          (WHADVP (WRB when))
          (S
            (VP (VBN compared)
              (PP (IN with)
                (NP (JJ male) (NNS subjects) (CD -LSB-9) (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NNS studies))
        (VP (VBG concerning)
          (NP
            (NP
              (NP (DT the) (JJ functional) (NN interaction))
              (PP (IN between)
                (NP (DT the) (JJ NF-κB) (NN pathway))))
            (CC and)
            (NP
              (NP (NNS members))
              (PP (IN of)
                (NP (DT the) (NN steroid) (NN hormone) (NN receptor) (NN family))))
            (, ,)
            (CC and)
            (NP
              (NP (PRP$ their) (NN role))
              (PP (IN in)
                (NP (JJ synovial) (NN inflammation))))))
        (, ,))
      (VP (VBP have)
        (VP (JJ advanced)
          (ADVP (RB significantly))
          (, ,)
          (SBAR (IN although)
            (FRAG
              (PP (IN with)
                (NP (JJ controversial) (NNS results) (NN -LSB-10,11)))
              (-RRB- -RSB-))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP (JJ particular)))
    (, ,)
    (PP (IN after)
      (S
        (VP (VBG binding)
          (PP (IN with)
            (NP (NN E2))))))
    (, ,)
    (NP (NN oestrogen) (NNS receptors))
    (VP (VBP have)
      (VP (VBN been)
        (VP (VBN shown)
          (S
            (VP (TO to)
              (VP (VB interact)
                (PP (IN with)
                  (NP (JJ NF-κB) (NNS factors)))
                (, ,)
                (PP (IN via)
                  (NP (JJ transcriptional) (NNS co-factors))))))))
      (, ,)
      (S
        (VP (VBG resulting)
          (PP (IN in)
            (NP
              (ADJP
                (ADJP (JJ mutual))
                (CC or)
                (ADJP (JJ non-mutual)))
              (NN antagonism))))))
    (. .)))

(
  (S
    (NP (JJ Other) (NNS studies))
    (VP (VBP hypothesize)
      (SBAR (IN that)
        (S (, ,)
          (SBAR (IN since)
            (S
              (NP (NN oestrogen) (NNS receptors))
              (VP (MD may)
                (VP (VB repress)
                  (NP
                    (ADJP (CC both)
                      (ADJP (JJ constitutive))
                      (CC and)
                      (ADJP (JJ inducible)))
                    (NN NF-κB) (NN activity))))))
          (, ,)
          (NP
            (NP (DT the) (NN overexpression))
            (PP (IN of)
              (NP (JJ NF-κB-inducible) (NNS genes)))
            (PP (IN in)
              (NP (NN oestrogen) (JJ receptor-negative) (NNS cells))))
          (VP (MD might)
            (VP (VB contribute)
              (PP (TO to)
                (NP
                  (NP (JJ malignant) (NN cell) (NN growth))
                  (CC and)
                  (NP (JJ chemotherapeutic) (NN resistance) (NN -LSB-12,13))))))
          (-RRB- -RSB-))))
    (. .)))

(
  (S
    (S
      (PP (IN On)
        (NP (DT the) (NN contrary)))
      (, ,)
      (NP (JJ further) (NNS studies))
      (VP (VBP report)
        (SBAR (IN that)
          (S
            (NP (NN E2))
            (VP (VBZ blocks)
              (NP
                (NP (DT the) (JJ transcriptional) (NN activity))
                (PP (IN of)
                  (NP (NN p65)))
                (PP (IN in)
                  (NP (NNS macrophages) (CD -LSB-14))))))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (ADVP (RB However))
      (, ,)
      (NP (DT these) (JJ opposite) (NNS observations))
      (VP (VBP arise)
        (S
          (VP (VBG using)
            (NP
              (NP
                (NP (JJ different) (NN cell) (NNS lines))
                (PRN (-LRB- -LRB-)
                  (NP (NNS human/animals))
                  (-RRB- -RRB-)))
              (CC and)
              (NP
                (NP (NN culture) (NNS conditions))
                (CONJP (RB as) (RB well) (IN as))
                (NP (JJ different) (NN hormone) (NNS concentrations))
                (NP (CD -LSB-15) (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP (NN addition)))
    (, ,)
    (NP
      (NP (JJ multiple) (NNS mechanisms))
      (VP (VBG concerning)
        (NP
          (NP (DT the) (NN interaction))
          (PP (IN between)
            (NP
              (NP (NN oestrogen) (NNS receptors))
              (CC and)
              (NP (NNS NF-κB)))))))
    (VP (VBP have)
      (VP (VBN been)
        (VP (VBN proposed) (, ,)
          (PP (JJ such) (IN as)
            (NP
              (NP (NN repression))
              (PP (IN of)
                (NP
                  (NP
                    (NP (JJ NF-κB) (NN DNA) (NN binding))
                    (PP (IN by)
                      (NP
                        (NP (JJ physical) (NN association))
                        (PP (IN with)
                          (NP (NN oestrogen) (NNS receptors))))))
                  (CC and)
                  (NP
                    (NP (DT the) (NN regulation))
                    (PP (IN of)
                      (NP (NN IκB-α) (NN expression))))))
              (PP (IN by)
                (NP (NNS oestrogens) (CD -LSB-16,17) (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN androgen) (NN receptor))
      (VP (VBZ seems)
        (S
          (VP (TO to)
            (VP (VB be)
              (ADJP (RB closely) (JJ related)
                (PP (TO to)
                  (NP
                    (NP (DT the) (NN glucocorticoid) (NN receptor))
                    (PP (IN in)
                      (NP
                        (NP (NNS terms))
                        (PP (IN of)
                          (NP (CC both)
                            (NP (NN structure))
                            (CC and)
                            (NP (NN sequence) (NN homology))))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN androgen) (NN receptor))
        (CC and)
        (NP (DT the) (NN glucocorticoid) (NN receptor)))
      (VP (VBP have)
        (VP (VBN been)
          (VP (VBN shown)
            (S
              (VP (TO to)
                (VP
                  (VP (VB interact))
                  (CC and)
                  (VP (VB repress)
                    (NP (NN activator) (NN protein) (CD 1))
                    (PP (IN via)
                      (NP (DT a) (JJ similar) (NN mechanism)))))))))))
    (: ;)
    (S
      (ADVP (RB consequently))
      (, ,)
      (NP (PRP it))
      (VP (MD would) (RB not)
        (VP (VB be)
          (ADJP (JJ surprising))
          (SBAR (IN that)
            (S
              (NP (DT the) (NN androgen) (NN receptor))
              (VP (MD might)
                (ADVP (RB also))
                (VP (VB interact)
                  (PP (IN with)
                    (NP (NN NF-κB)))
                  (PP (IN in)
                    (NP
                      (NP (DT a) (NN manner))
                      (ADJP (RB very) (JJ similar)
                        (PP (TO to)
                          (NP
                            (NP (DT that))
                            (VP (VBN observed)
                              (PP (IN for)
                                (NP (DT the) (NN glucocorticoid) (NN receptor) (NN -LSB-18)))))))
                      (-RRB- -RSB-))))))))))
    (. .)))

(
  (S
    (S
      (NP (CC Both)
        (NP (DT the) (NN androgen) (NN receptor))
        (CC and)
        (NP (NN NF-κB)))
      (VP (VBP are)
        (NP
          (NP
            (NP (JJ inducible) (NN transcription) (NNS factors))
            (PP (IN with)
              (NP
                (NP (DT some) (JJ opposing) (NNS functions))
                (PP (IN in)
                  (NP
                    (NP (DT the) (NN regulation))
                    (PP (IN of)
                      (NP
                        (ADJP
                          (ADJP (JJ immune))
                          (CC and)
                          (ADJP (JJ inflammatory)))
                        (NNS responses))))))))
          (NP (CD -LSB-19) (-RRB- -RSB-)))))
    (. .)))

(
  (S
    (S
      (S
        (NP (PRP It))
        (VP (VBZ is)
          (ADJP (JJ possible))
          (SBAR (IN that)
            (S
              (NP
                (NP (JJ inflammatory) (NNS agents))
                (SBAR
                  (WHNP (WDT that))
                  (S
                    (VP (VBP activate)
                      (NP (NN NF-κB))
                      (ADVP (FW in) (FW vivo))))))
              (VP (MD may)
                (VP (VB interfere)
                  (PP (IN with)
                    (NP (JJ normal) (NN androgen) (NN signalling)))))))))
      (, ,)
      (CC and)
      (S
        (NP (JJ recent) (NNS studies))
        (VP (VBP indicate)
          (SBAR (IN that)
            (S
              (NP
                (NP (DT the) (NN androgen) (NN receptor))
                (CC and)
                (NP
                  (NP (NN NF-κB))
                  (PRN (-LRB- -LRB-)
                    (NP (NN subunit) (NN p65))
                    (-RRB- -RRB-))))
              (VP (VBP are)
                (NP
                  (NP (JJ mutual) (JJ transcriptional) (NNS antagonists))
                  (CD -LSB-20) (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (JJ present) (NN study))
      (VP (VBD was)
        (ADVP (RB therefore))
        (VP (VBN undertaken)
          (S
            (VP (TO to)
              (VP (VB examine)
                (NP
                  (NP (DT the)
                    (ADJP
                      (ADJP (JJ long-term))
                      (PRN (-LRB- -LRB-)
                        (NP
                          (NP (NN time) (NN course))
                          (PP (IN of)
                            (NP (CD 7) (NNS days))))
                        (-RRB- -RRB-)))
                    (NNS effects))
                  (PP (IN of)
                    (NP (NN sex) (NNS hormones)))
                  (PP (IN on)
                    (NP (VBN activated) (VBN cultured) (JJ human) (JJ monocytic/macrophage) (NN cell) (NN line) (-LRB- -LRB-) (NN THP-1) (-RRB- -RRB-) (NNS cells))))
                (PP (IN by)
                  (S
                    (VP (VBG investigating)
                      (NP
                        (NP (PRP$ their) (NNS effects))
                        (PP (IN on)
                          (NP (NN cell)
                            (NP
                              (NP (NN proliferation))
                              (CC and)
                              (NP (NN apoptosis)))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS cells))
      (VP
        (VP (VBP are)
          (VP (VBN equipped)
            (PP (IN with)
              (NP (JJ functional) (NN sex) (NN hormone) (NNS receptors)))))
        (CC and)
        (VP (VBP are)
          (NP
            (NP (DT an) (JJ important) (NN target))
            (PP (IN of)
              (NP (NN sex) (NN steroid) (NNS hormones))))
          (, ,)
          (ADVP (RB particularly))
          (PP (IN in)
            (NP
              (NP (JJ inflammatory) (NNS diseases))
              (PP (JJ such) (IN as)
                (NP
                  (NP (JJ rheumatoid) (NN arthritis))
                  (PRN (-LRB- -LRB-)
                    (NP (NN RA) (-RRB- -RRB-) (CD -LSB-21))
                    (-RRB- -RSB-)))))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP (JJ particular)))
    (, ,)
    (PP (IN in)
      (NP (DT the) (JJ present) (NN study)))
    (NP (PRP we))
    (VP (VBD used)
      (NP
        (NP
          (NP
            (NP (JJ pharmacological) (NNS concentrations))
            (PP (IN of)
              (NP (NN E2))))
          (PRN (-LRB- -LRB-)
            (NP (JJ final) (NN concentration))
            (, ,)
            (NP
              (NP (CD 10) (NN nM))
              (: ;)
              (NP (NNP Sigma-Aldrich) (, ,) (NNP Milan) (, ,) (NNP Italy)))
            (-RRB- -RRB-)))
        (SBAR
          (WHNP (WDT that))
          (S
            (VP (VBP have)
              (VP (VBN been)
                (ADVP (RB already))
                (VP (VBN described)
                  (PP (IN as)
                    (NP
                      (NP (DT the) (RBS most) (JJ efficient))
                      (PP (IN in)
                        (NP
                          (NP (JJ stimulating) (NNS macrophages))
                          (PP (IN in)
                            (NP (FW vitro) (NN -LSB-22) (-RRB- -RSB-))))))))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Accordingly))
      (, ,)
      (NP (DT the) (JJ same) (NN concentration))
      (VP (VBZ has)
        (VP (VBN been)
          (VP (VBN used)
            (PP (IN for)
              (NP (NN testosterone) (NN -LSB-23))))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (ADVP (RB therefore))
      (VP (VBD investigated)
        (NP
          (NP (NN sex) (NN hormone) (NNS effects))
          (PP (IN on)
            (NP (DT the) (JJ NF-κB) (NN pathway))))
        (, ,)
        (PP (IN as)
          (NP
            (NP (DT a) (NN complex))
            (PP (IN of)
              (NP
                (NP (NNS molecules))
                (VP (VBG modulating)
                  (NP (JJ cellular) (NNS responses))
                  (PP (IN in)
                    (NP (VBN activated) (NNS cells))))))))))
    (. .)))

(
  (S
    (NP
      (NP (NNS Materials))
      (CC and)
      (NP (NNS methods)))))

(
  (S
    (S
      (NP
        (NP (NN THP-1) (NNS cells))
        (PRN (-LRB- -LRB-)
          (NP
            (NP
              (NP (NN Interlab) (NN cell) (NN line))
              (NP (NN collection) (CD HTL097014)))
            (: ;)
            (NP (JJ IST) (NN c/o) (NN CBA))
            (, ,)
            (NP (NNP Genoa) (, ,) (NNP Italy)))
          (-RRB- -RRB-)))
      (VP (VBD were)
        (VP (VBN cultured)
          (PP (IN in)
            (NP
              (NP (NN RPMI-1640) (NN medium))
              (VP (VBN supplemented)
                (PP (IN with)
                  (NP
                    (NP
                      (NP
                        (ADJP (CD 2) (NN %))
                        (JJ foetal) (JJ bovine) (NN serum))
                      (PRN (-LRB- -LRB-)
                        (NP (NN Sigma-Aldrich))
                        (-RRB- -RRB-)))
                    (PRN (-LRB- -LRB-)
                      (NP
                        (NP
                          (ADJP (CD 5) (NN %))
                          (NN CO2) (JJ humidified) (NN atmosphere))
                        (PP (IN at)
                          (NP (NN 37°C))))
                      (-RRB- -RRB-))))))))))
    (. .)))

(
  (S
    (ADVP (RB Moreover))
    (, ,)
    (NP
      (NP (DT the) (NN absence))
      (PP (IN of)
        (NP
          (NP (NN binding))
          (PP (IN of)
            (NP (DT the) (NNS hormones)))
          (PP (IN with)
            (NP
              (NP (JJ other) (JJ foetal) (NN bovine) (NN serum) (NNS components))
              (ADJP (JJ related)
                (PP (TO to)
                  (NP
                    (NP (NN growth) (NN rate))
                    (CC and)
                    (NP
                      (NP (DT the) (NN survival))
                      (PP (IN of)
                        (NP (VBN cultured) (NN THP-1) (NNS cells)))
                      (PP (IN over)
                        (NP
                          (NP (DT the) (NN course))
                          (PP (IN of)
                            (NP (CD 7) (NNS days))))))))))))))
    (VP (VBD were)
      (VP (VBN investigated)))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NNS cells))
      (VP (VBD were)
        (VP (VBN maintained)
          (PP (IN in)
            (NP (JJ logarithmic) (NN growth)))
          (PP (IN by)
            (NP (NN passage)
              (NP (DT every) (CD 3–4) (NNS days)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN viability))
        (PP (IN of)
          (NP
            (NP (DT the) (NNS cells))
            (PRN (-LRB- -LRB-)
              (NP (CD 97–98) (NN %))
              (-RRB- -RRB-)))))
      (VP (VBD was)
        (VP (VBN tested)
          (PP (IN by)
            (NP (DT the)
              (NP (NN Trypan) (JJ blue) (NN exclusion))
              (NN procedure))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Briefly))
      (, ,)
      (NP (DT the) (NNS cells))
      (VP
        (VP (VBD were)
          (VP (VBN seeded)
            (PP (IN into)
              (NP
                (NP (JJ six-well) (JJ flat-bottom) (NNS plates))
                (PRN (-LRB- -LRB-)
                  (NP (CD 106) (NNS cells/well))
                  (-RRB- -RRB-))))))
        (CC and)
        (VP (VBD were)
          (VP (VBN treated)
            (PP (IN with)
              (NP
                (NP
                  (ADJP (CD 500) (NN U/ml))
                  (NN IFN-γ))
                (PRN (-LRB- -LRB-)
                  (NP (NN Sigma-Aldrich))
                  (-RRB- -RRB-))))
            (SBAR (IN in) (NN order)
              (S
                (VP (TO to)
                  (VP (VB differentiate)
                    (NP (NN THP-1))
                    (PP (IN into)
                      (NP (NN macrophage) (NNS cells) (CD -LSB-24) (-RRB- -RSB-)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The)
          (NP (NN activation))
          (CC and)
          (NP (NN transformation)))
        (PP (IN of)
          (NP (DT the) (NNS cells))))
      (VP (VBD was)
        (VP (VBN evaluated)
          (PP (IN by)
            (NP
              (NP
                (NP
                  (NP (DT the) (NN expression))
                  (PP (IN of)
                    (NP (JJ different) (NN macrophage) (NNS antigens))))
                (: :)
                (NP (NN CD68))
                (, ,)
                (NP (NN CD14))
                (, ,)
                (NP (NN HAM) (CD 56)))
              (, ,)
              (NP (NN Mac) (CD 387)))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN THP-1) (JJ activated) (NNS cells))
      (VP (VBD were)
        (ADVP (RB then))
        (VP (VBN incubated)
          (PP (IN for)
            (NP
              (QP (CD 24) (, ,) (CD 48) (, ,) (CD 72) (, ,) (CD 96)
                (CC and)
                (CD 168))
              (NNS hours)))
          (PP (IN with)
            (NP
              (NP
                (NP (NN E2))
                (CC and)
                (NP (NN testosterone)))
              (PRN (-LRB- -LRB-)
                (NP (CD 10) (NN nM))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (PP (IN After)
        (NP (DT that) (NN time)))
      (NP
        (NP (NNS samples))
        (PP (IN of)
          (NP (NN THP-1) (NNS cells))))
      (VP (VBD were)
        (ADVP (RB also))
        (VP (VBN treated)
          (PP (IN with)
            (NP
              (NP (DT an) (NN apoptosis) (NN inducer) (CD -LSB-25) (-RRB- -RSB-))
              (, ,)
              (NP
                (NP (NN staurosporine))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (CD 17) (NN nM))
                    (: ;)
                    (NP (NN Sigma) (NN Aldrich)))
                  (-RRB- -RRB-)))
              (, ,)))
          (PP (IN for)
            (NP (CD 24) (NNS hours))))))
    (. .)))

(
  (S
    (S
      (PP (IN At)
        (NP
          (NP (DT the) (NN end))
          (PP (IN of)
            (NP (DT the) (JJ different) (NN incubation) (NNS times)))))
      (, ,)
      (NP (DT the) (NNS cells))
      (VP (VBD were)
        (VP
          (VP (VBN harvested))
          (, ,)
          (VP (VBN washed)
            (PP (IN in)
              (NP
                (NP
                  (NP (NN Dulbecco) (POS 's))
                  (JJ phosphate-buffered) (NN saline))
                (PRN (-LRB- -LRB-)
                  (NP (NN DPBS))
                  (-RRB- -RRB-)))))
          (CC and)
          (VP (VBN treated)
            (PP (IN with)
              (NP
                (NP (JJ different) (NN lysis) (NNS buffers))
                (PP (IN for)
                  (NP (DT the)
                    (ADJP
                      (ADJP (JJ nuclear))
                      (CC and)
                      (ADJP (JJ total)))
                    (NN protein) (NN extraction)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Part))
        (PP (IN of)
          (NP (DT the) (NN cell))))
      (VP (VBD was)
        (ADVP (RB then))
        (VP (VBN collected)
          (PP
            (PP (IN for)
              (NP
                (NP
                  (NP
                    (NP (NN DNA) (NN content))
                    (PRN (-LRB- -LRB-)
                      (ADJP
                        (ADJP (JJ normal))
                        (CC and)
                        (ADJP (JJ apoptotic)))
                      (-RRB- -RRB-)))
                  (NN evaluation))
                (PP (IN by)
                  (NP (NN flow) (NN analysis) (NN cytometry) (NN scatter) (NN analysis)))))
            (CC and)
            (PP (IN for)
              (NP (NN immunocytochemistry) (NN analysis)))))))
    (. .)))

(
  (S
    (NP
      (NP (DT The) (NN immunocytochemistry) (NN analysis))
      (VP (TO to)
        (VP (VB evaluate)
          (NP
            (NP (DT the) (NN expression))
            (PP (IN of)
              (NP
                (NP (NN CD68))
                (, ,)
                (NP (NN CD14))
                (, ,)
                (NP (NN HAM56))
                (CC and)
                (NP (NN Mac387))))
            (PP (IN in)
              (NP (DT the) (JJ treated) (NNS cells)))))))
    (VP (VBD showed)
      (NP
        (NP (JJ positive) (NNS results))
        (PRN (-LRB- -LRB-)
          (S
            (NP (NNS data))
            (VP (RB not) (VBN shown)))
          (-RRB- -RRB-)))
      (, ,)
      (S
        (VP (VBG confirming)
          (NP
            (NP (DT the) (NN activation))
            (PP (IN of)
              (NP (NNS monocytes)))
            (PP (IN by)
              (NP (NN IFN-γ)))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN cell) (NN growth))
      (VP (VBD was)
        (VP (VBN evaluated)
          (PP (IN at)
            (NP (JJ different) (NNS times)))
          (PP (IN by)
            (NP
              (NP (DT the) (JJ methyl-tetrazolium) (NN salt) (NN test))
              (, ,)
              (SBAR
                (WHNP (WDT which))
                (S
                  (VP (VBZ represents)
                    (NP
                      (NP (DT a) (JJ quantitative) (JJ colorimetric) (NN assay))
                      (S
                        (VP (TO to)
                          (VP (VB detect)
                            (NP (NN cell)
                              (NP (NN survival))
                              (CC and)
                              (NP (NN proliferation)))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN test))
      (VP (VBZ is)
        (VP (VBN based)
          (PP (IN on)
            (NP
              (NP (DT the) (NN ability))
              (PP (IN of)
                (NP (VBG living) (NNS cells)))
              (S
                (VP (TO to)
                  (VP (VB cleave)
                    (NP (DT the) (NN tetrazolium) (NN ring))
                    (PP (IN at)
                      (NP
                        (NP (DT the) (NN level))
                        (PP (IN of)
                          (NP (JJ active) (NN mitochondria)))))))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Briefly))
      (, ,)
      (NP (DT the) (NNS cells))
      (VP
        (VP (VBD were)
          (VP (VBN seeded)
            (PP (IN into)
              (NP (JJ 96-well) (NN microtitre) (NNS plates)))))
        (CC and)
        (VP (VBD were)
          (VP (VBN treated)
            (PP (VBG according)
              (PP (TO to)
                (NP (DT the) (JJ experimental) (NN design))))))))
    (. .)))

(
  (S
    (S
      (PP (IN At)
        (NP (DT the) (JJ established) (NN time)))
      (, ,)
      (NP
        (NP
          (NP
            (ADJP (CD 50) (NN μl))
            (NN methyl-tetrazolium) (NN salt) (NN labelling))
          (NN reagent) (NN -LSB-3-) (-LRB- -LRB-) (NN 4,5-dimethylthiazol-2-yl) (-RRB- -RRB-) (NN -2,5-diphenyltetrazolium) (NN bromide))
        (PRN (, ,)
          (NP
            (NP (CD 5) (NN mg/ml))
            (PP (IN in)
              (NP (NNS PBS))))
          (-RRB- -RSB-)))
      (VP (VBD was)
        (VP
          (VP (VBN added)
            (PP (TO to)
              (NP (DT each) (NN well))))
          (CC and)
          (VP (VBN incubated)
            (PP (IN in)
              (NP (JJ humidified) (NN atmosphere)))
            (PP (IN at)
              (NP (NN 37°C)))))))
    (. .)))

(
  (S
    (S
      (ADVP
        (NP (CD Four) (NNS hours))
        (RB later))
      (, ,)
      (NP (CD 100) (NN μl) (NN dimethylsulfoxide))
      (VP (VBD were)
        (VP
          (VP (VBN introduced)
            (PP (IN into)
              (NP (DT each) (NN well))))
          (CC and)
          (VP (VBN mixed)
            (ADVP (RB thoroughly))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN absorbance))
      (VP (VBD was)
        (VP (VBN calculated)
          (PP (IN at)
            (NP (CD 540) (NN nm)))
          (, ,)
          (S
            (VP (VBG using)
              (NP (DT a) (NN scanning) (NN multiwell) (NN spectrophotometer)))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Standard) (NNS curves))
      (VP (VBD were)
        (VP (VBN constructed)
          (PP (IN for)
            (NP
              (NP (NN THP-1) (NNS cells))
              (VP (VBG using)
                (NP (JJ known) (NN plating) (NNS densities)))))
          (, ,)
          (S
            (VP (VBG allowing)
              (S
                (NP (DT the) (NN cell) (NN number))
                (VP (TO to)
                  (VP (VB be)
                    (VP (VBN calculated)
                      (PP (IN from)
                        (NP (DT this) (JJ optical) (NN density) (NN reading))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT Each) (NN experiment))
      (VP (VBD was)
        (VP (VBN performed)
          (PP (IN in)
            (NP (NN triplicate))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (JJ apoptotic) (NNS events))
      (VP (VBD were)
        (VP (VBN evaluated)
          (PP (IN after)
            (NP
              (NP (CD 168) (NNS hours))
              (PP (IN from)
                (NP (CC both)
                  (NP (NN sex) (NN hormone) (NN stimulation))
                  (CC and)
                  (NP
                    (NP (NN staurosporine) (NN treatment))
                    (PRN (-LRB- -LRB-)
                      (NP
                        (NP (CD 17) (NN nM))
                        (PP (IN for)
                          (NP (CD 24) (NNS hours))))
                      (-RRB- -RRB-)))))))
          (PP (IN by)
            (NP
              (NP (NN annexin) (NN V-propidium) (NN iodide) (NN analysis))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (NN MBL) (NN Co.))
                  (, ,)
                  (NP (NNP Ltd) (, ,) (NNP Nagoya) (, ,) (NNP Japan)))
                (-RRB- -RRB-))))
          (, ,)
          (SBAR (IN in) (NN order)
            (S
              (VP (TO to)
                (VP (VB detect)
                  (NP
                    (NP
                      (NP (DT the) (JJ early-stage) (NN apoptosis))
                      (PRN (-LRB- -LRB-)
                        (NP
                          (NP (NNS cells))
                          (ADJP (RB only) (JJ annexin-positive)))
                        (-RRB- -RRB-)))
                    (CC and)
                    (NP
                      (NP (DT the) (JJ late-stage) (NN apoptosis))
                      (PRN (-LRB- -LRB-)
                        (NP
                          (NP (NNS cells))
                          (ADJP
                            (ADJP (JJ annexin-positive))
                            (CC and)
                            (ADJP (JJ propidium-positive))))
                        (-RRB- -RRB-)))))))))))
    (. .)))

(
  (S
    (PP (IN After)
      (S
        (VP (VBG resuspending)
          (NP
            (NP (DT the) (NNS cells))
            (PRN (-LRB- -LRB-)
              (NP (CD 1) (NN ×) (CD 105))
              (-RRB- -RRB-)))
          (PP (IN into)
            (NP
              (NP (CD 200) (NN μl))
              (PP (IN of)
                (NP (CD 1) (NN x) (NN binding) (NN buffer))))))))
    (, ,)
    (NP
      (NP (CD 1) (JJ μl) (JJ fluorescein-labelled) (NN annexin) (NN V))
      (CC and)
      (NP
        (ADJP (CD 1) (NN μl))
        (NN propidium) (NN iodide)))
    (VP (VBD were)
      (VP (VBN added)))
    (. .)))

(
  (S
    (S
      (ADVP (RB Then))
      (NP (DT the) (NNS cells))
      (VP (VBD were)
        (VP (VBN incubated)
          (PP (IN for)
            (NP (CD 5) (NN min)))
          (PP (IN at)
            (NP
              (NP (JJ room) (NN temperature))
              (PRN (-LRB- -LRB-)
                (NP (NN dark) (NN light))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Finally))
      (, ,)
      (NP (DT the) (NNS cells))
      (VP (VBD were)
        (VP
          (VP (VBN plated)
            (PP (IN on)
              (NP (JJ glass) (NNS slides))))
          (CC and)
          (VP (VBN analysed)
            (PP (IN by)
              (NP
                (NP (NN fluorescence) (NN microscopy))
                (PRN (-LRB- -LRB-)
                  (NP (CD 550) (NN nm))
                  (-RRB- -RRB-))))
            (PP (IN for)
              (NP
                (NP (DT a) (NN total))
                (PP (IN of)
                  (NP
                    (NP (CD 500) (NNS cells))
                    (PP (IN per)
                      (NP
                        (NP (NN sample))
                        (, ,)
                        (SBAR
                          (WHNP (WDT which))
                          (S
                            (VP (VBZ allows)
                              (NP
                                (NP (NN detection))
                                (PP
                                  (ADVP (RB even))
                                  (IN of)
                                  (NP (DT a) (JJ single) (JJ apoptotic) (NN cell)))))))))))))))))
    (. .)))

(
  (S
    (S
      (S
        (VP (TO To)
          (VP (VB confirm)
            (NP
              (NP (DT the) (VBN reduced) (NN DNA) (NN content))
              (PRN (-LRB- -LRB-)
                (NP (JJ oligonucleosomal-size) (NNS fragments))
                (-RRB- -RRB-))))))
      (NP
        (NP (DT the) (NNS cells))
        (VP (VBN stimulated)
          (PP
            (PP (IN with)
              (NP (NNS hormones)))
            (, ,)
            (PP (IN without)
              (CC and)
              (PP (IN with)
                (NP (NN staurosporine))))
            (, ,)
            (PP (IN after)
              (NP (NN fixation))))))
      (VP
        (VP (VBD were)
          (VP (VBN stained)
            (PP (IN with)
              (NP
                (NP (NN intercalating) (NNS dyes))
                (PRN (-LRB- -LRB-)
                  (NP (NN propidium) (NN iodide))
                  (-RRB- -RRB-))))))
        (CC and)
        (VP (VBD were)
          (VP (VBN analysed)
            (PP (IN by)
              (NP
                (NP (NN flow) (NN analysis) (NN cytometry))
                (ADJP (JJ scatter)
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (JJ Becton-Dickinson-Immunocytometry) (NNS Systems))
                      (, ,)
                      (NP (NNP Erembodegem) (, ,) (NNP Belgium)))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (NP (NN THP-1) (NNS cells))
      (VP (VBD were)
        (VP (VBN harvested)
          (PP (IN at)
            (NP
              (NP (DT a) (NN concentration))
              (PP (IN of)
                (NP (CD 5) (NN ×) (CD 103)))))
          (, ,)
          (S
            (VP (VBG being)
              (VP (VBD sedimented)
                (PP (IN on)
                  (NP
                    (NP (JJ poly-L-lysine-coated) (NN glass) (NNS slides))
                    (PP (IN for)
                      (NP
                        (NP (CD 40) (NN min))
                        (PP (IN at)
                          (NP (NN 4°C)))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NNS spots))
      (VP (VBD were)
        (ADVP (RB then))
        (ADJP
          (ADJP (JJ air-dried))
          (CC and)
          (ADJP (JJ fixed)))
        (PP (IN in)
          (NP
            (NP (JJ cold) (NN acetone))
            (PP (IN for)
              (NP (CD 30) (NN s)))))))
    (, ,)
    (CC and)
    (S
      (VP (VBN stored)
        (PP (IN at)
          (NP (NN -20°C)))
        (PP (IN until)
          (NP
            (NP (DT the) (NN immunodetermination))
            (PP (IN of)
              (NP
                (NP (NN poly-ADP) (NN ribose) (NN polymerase) (-LRB- -LRB-) (NN PARP) (-RRB- -RRB-) (JJ -cleaved) (NN expression))
                (, ,)
                (NP (VBG proliferating) (NN cell) (JJ nuclear) (NN antigen) (-LRB- -LRB-) (NN PCNA) (-RRB- -RRB-) (NN expression))
                (, ,)
                (NP (NN NF-κB))
                (, ,)
                (NP (NN IκB-α))
                (CC and)
                (NP
                  (NP (NN IκB-α-ser) (CD 32))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (NNP Santa) (NNP Cruz) (NN Biotechnology))
                      (, ,)
                      (NP (NNP Santa) (NNP Cruz))
                      (, ,)
                      (NP (NN CA))
                      (, ,)
                      (NP (NN USA)))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (PP (IN After)
        (NP
          (NP (NN rehydration))
          (PP (IN in)
            (NP (NNS PBS)))))
      (, ,)
      (NP (NNS spots))
      (VP (VBD were)
        (VP (VBN incubated)
          (PP (IN with)
            (NP (DT the) (JJ anti-human) (NN antibody)))
          (PP (IN at)
            (NP
              (NP (JJ different) (NNS dilutions))
              (PP (IN at)
                (NP (JJ room) (NN temperature))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The)
        (ADJP
          (ADJP (JJ second))
          (CC and)
          (ADJP (JJ third)))
        (NNS steps))
      (VP (VBD were)
        (VP (VBN performed)
          (S
            (VP (VBG using)
              (NP
                (NP (DT the) (JJ improved) (JJ biotin-streptavidin-amplified) (NN detection) (NN system))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (NN Vector) (NNS Laboratories))
                    (NP
                      (NP (NNP Inc.) (, ,) (NNP Burlingame))
                      (, ,)
                      (NP (NN CA))
                      (, ,)
                      (NP (NNP USA))))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (S
        (ADVP (RB Briefly))
        (, ,)
        (PP (VBG according)
          (PP (TO to)
            (NP (DT this) (NN method))))
        (, ,)
        (NP (NNS cells))
        (VP (VBD were)
          (VP (VBN incubated)
            (PP (IN with)
              (NP
                (NP (DT the) (JJ secondary) (NN antibody))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (VBN biotinylated) (NN IgG))
                    (, ,)
                    (NP (CD 1:20) (NN dilution)))
                  (-RRB- -RRB-))))
            (PP (IN for)
              (NP
                (NP (CD 20) (NN min))
                (PP (IN at)
                  (NP (JJ room) (NN temperature))))))))
      (CC and)
      (S
        (ADVP (RB then))
        (, ,)
        (PP (IN after)
          (NP
            (NP (JJ several) (NNS washes))
            (PP (IN in)
              (NP (NNS PBS)))))
        (, ,)
        (NP (NNS cells))
        (VP (VBD were)
          (VP (VBN treated)
            (PP (IN with)
              (NP
                (NP (DT the) (JJ concentrated) (NN enzyme) (VB label))
                (PRN (-LRB- -LRB-)
                  (NP (NN biotin-streptavidin-peroxidase))
                  (-RRB- -RRB-)
                  (PP (IN for)
                    (NP
                      (NP (CD 20) (NN min))
                      (CC and)
                      (, ,)
                      (ADVP (RB finally))
                      (, ,)
                      (VP (VBN incubated)
                        (PP (IN at)
                          (NP (JJ room) (NN temperature)))
                        (PP (IN with)
                          (NP
                            (NP
                              (NP (DT the) (JJ peroxidase-substrate) (NN solution))
                              (PRN (-LRB- -LRB-)
                                (NP (CD 0.04) (NN %) (NN 3,3-diaminobenzidine) (NN -LSB-Sigma-Aldrich))
                                (-RRB- -RSB-)))
                            (PP (IN in)
                              (NP
                                (NP
                                  (ADJP (CD 50) (NN mM))
                                  (NN Tris-HCl) (NN buffer))
                                (VP (VBG containing)
                                  (NP
                                    (ADJP (CD 0.3) (NN %))
                                    (NN hydrogen) (NN peroxide))))))))))
                  (-RRB- -RRB-))))
            (PP (IN for)
              (NP (CD 15) (NN min)))))))
    (. .)))

(
  (S
    (PP (IN After)
      (NP
        (NP (JJ rinsing))
        (PP (IN with)
          (NP (NNS PBS)))))
    (, ,)
    (NP (NNS slides))
    (VP
      (VP (VBD were)
        (ADJP (JJ counterstained)
          (PP (IN with)
            (NP (NN haematoxylin)))))
      (, ,)
      (VP (VBD were)
        (VP
          (VP (VBN dried))
          (CC and)
          (VP (VBP cover)
            (VP (VBN slipped)
              (PP (IN with)
                (NP (NN Eukitt)))))))
      (, ,)
      (CC and)
      (VP (VBD were)
        (VP (VBN examined)
          (PP (IN by)
            (NP
              (NP (JJ light) (NN microscopy))
              (CC and)
              (NP (VBN computerized) (NN image) (NN analysis)))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Controls))
      (VP (VBD were)
        (VP (VBN treated)
          (ADVP (RB identically))
          (, ,)
          (PP (IN except)
            (PP (IN for)
              (S
                (VP (VBG omitting)
                  (NP (DT the)
                    (ADJP
                      (ADJP (JJ primary))
                      (CC or)
                      (ADJP (JJ secondary)))
                    (NNS antibodies)))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Image) (NN analysis))
      (VP (VBD was)
        (VP (VBN performed)
          (PP (IN with)
            (NP (DT the) (NN Leica) (NN Q500) (NN MC) (NN Image) (NN Analysis) (NN System)))
          (PRN (-LRB- -LRB-)
            (NP
              (NP (NNP Leica))
              (, ,)
              (NP (NN Cambridge))
              (, ,)
              (NP (NNP UK)))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (S
        (PP (IN For)
          (NP (DT each) (NN sample)))
        (, ,)
        (NP (CD 100) (NNS cells))
        (VP (VBD were)
          (ADVP (RB randomly))
          (VP (VBN analysed))))
      (CC and)
      (S
        (NP
          (NP (DT the) (NNS pixels))
          (PP (IN per)
            (NP
              (NP (NN micron) (NN square))
              (PRN (-LRB- -LRB-)
                (NP (JJ positive) (NN area))
                (-RRB- -RRB-)))))
        (VP (VBD were)
          (VP (VBN quantified)
            (PP (IN by)
              (NP (DT the) (NN Leica) (NN Q500) (NN software)))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (JJ single) (NNS cells))
      (VP (VBD were)
        (VP
          (VP
            (ADVP (RB randomly))
            (VBN selected)
            (PP (IN by)
              (NP
                (NP (DT the) (NNS operators))
                (VP (VBG using)
                  (NP (DT the) (NN cursor))))))
          (CC and)
          (VP (RB then)
            (ADVP (RB automatically))
            (VBN measured)
            (PP (IN as)
              (NP (DT the) (JJ positive) (NN area)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT A) (JJ constant) (NN optical) (NN threshold))
        (CC and)
        (NP (NN filter) (NN combination)))
      (VP (VBD was)
        (VP (VBN set)
          (S
            (VP (TO to)
              (VP (VB select)
                (NP (RB only) (DT the) (JJ positive) (NNS cells))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (DT The) (NNS results))
        (VP (VBD were)
          (VP (VBN analysed)
            (PP (IN by)
              (NP
                (NP (DT the) (NN analysis))
                (PP (IN of)
                  (NP
                    (NP (NN variance) (JJ non-parametric) (NN test))
                    (PRN (-LRB- -LRB-)
                      (NP (NN Bonferroni) (NN test))
                      (-RRB- -RRB-)))))))))
      (, ,)
      (CC and)
      (S
        (NP (DT the) (NNS values))
        (VP (VBP are)
          (VP (VBN presented)
            (PP (IN as)
              (NP
                (NP (NNS means))
                (VP (VBG ±)
                  (NP (JJ standard) (NNS deviations)))))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Cells))
      (VP (VBD were)
        (VP (VBN lysed)
          (PP (IN in)
            (NP
              (NP (NN buffer))
              (VP (VBG containing)
                (NP
                  (NP
                    (ADJP (CD 20) (NN mM))
                    (NN Tris-HCl))
                  (, ,)
                  (NP
                    (ADJP (CD 150) (NN mM))
                    (NN NaCl))
                  (, ,)
                  (NP
                    (ADJP (CD 1) (NN mM))
                    (NN phenylmethylsulfonylfluoride))
                  (, ,)
                  (NP
                    (ADJP (CD 5) (NN mg/ml))
                    (NN aprotinin))
                  (, ,)
                  (NP
                    (NP
                      (ADJP (CD 0.5) (NN %))
                      (NN Nonidet) (NN P-40))
                    (PRN (-LRB- -LRB-)
                      (NP (NN Sigma-Aldrich))
                      (-RRB- -RRB-)))))))
          (PP (IN for)
            (NP
              (NP (CD 1) (NN hour))
              (PP (IN at)
                (NP (NN 4°C))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NNS lysates))
      (VP (VBD were)
        (VP (VBN centrifuged)
          (PP (IN for)
            (NP (CD 10) (NN min)))
          (PP (IN at)
            (NP (CD 13,000) (NN rpm))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NNS surnatants))
      (VP (VBD were)
        (VP
          (VP (VBN collected))
          (CC and)
          (VP (VBN stored)
            (PP (IN at)
              (NP (NN -80°C)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NNS samples))
        (PP (IN of)
          (NP (NNS surnatants))))
      (VP
        (VP (VBD were)
          (ADVP (RB thereafter))
          (VP (VBN diluted)
            (PP (IN with)
              (NP (NN reducing) (NN sample) (NN buffer)))))
        (CC and)
        (VP (VBD were)
          (VP (VBN separated)
            (PP (IN by)
              (NP (NN electrophoresis)))
            (PP (IN on)
              (NP
                (NP (DT a)
                  (ADJP (CD 10) (NN %))
                  (NN SDS-PAGE) (NN gel))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (CD 20) (NN μg) (NN protein))
                    (PP (IN per)
                      (NP (NNP lane)))
                    (VP (VBN loaded)))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NNS proteins))
      (VP (VBD were)
        (VP (VBN transferred)
          (PP (IN onto)
            (NP
              (NP (NN Hybond-C-nitrocellulose) (NN membrane))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (NNP Amersham) (NNP Italia))
                  (, ,)
                  (NP (NNP Milan) (, ,) (NNP Italy)))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN reaction))
      (VP (VBD was)
        (VP (VBN blocked)
          (PP (IN by)
            (NP
              (NP (NNS DPBS))
              (PP (IN with)
                (NP
                  (ADJP (CD 5) (NN %))
                  (NN non-fat) (JJ powdered) (NN milk)))))
          (PP (IN at)
            (NP (JJ 4°C) (JJ overnight))))))
    (. .)))

(
  (S
    (PP (IN For)
      (NP (NN immunoblot) (NN analysis)))
    (, ,)
    (NP (DT the) (NNS membranes))
    (VP
      (VP (VBD were)
        (VP (VBN incubated)
          (PP (IN with)
            (NP (DT the) (JJ different) (NNS antibodies)))
          (PP (IN for)
            (NP
              (NP
                (NP
                  (NP (CD 1) (NN hour))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP
                        (NP (NNP NF-κB))
                        (, ,)
                        (NP (NNP IκB-α))
                        (, ,)
                        (NP (NNP IκB-α-ser) (CD 32))
                        (, ,)
                        (ADVP (RB respectively)))
                      (: ;)
                      (NP
                        (NP (NNP Santa) (NNP Cruz))
                        (NP (NN Biotechnology))))
                    (-RRB- -RRB-)))
                (PRN (-LRB- -LRB-)
                  (NP (NN dilution) (NN 1:200))
                  (-RRB- -RRB-)))
              (PP (IN in)
                (NP
                  (NP (NNS DPBS))
                  (PP (IN at)
                    (NP (JJ room) (NN temperature)))
                  (PP (IN with)
                    (NP (JJ constant) (NN shaking)))))))))
      (, ,)
      (CC and)
      (VP (VBD were)
        (VP (VBN washed)
          (ADVP (RB extensively))
          (PP (IN in)
            (NP
              (NP
                (ADJP (CD 0.05) (NN %))
                (NP (NNP DPBS/Tween) (CD 20)))
              (, ,)
              (NP (NN pH) (CD 7.4)))))))
    (. .)))

(
  (S
    (ADVP (RB Finally))
    (, ,)
    (NP (DT the) (NNS membranes))
    (VP (VBD were)
      (VP (VBN incubated)
        (PP (IN with)
          (NP
            (NP
              (NP (JJ secondary) (NN horseradish) (JJ peroxidase-labelled) (JJ polyclonal) (NN anti-goat) (NN IgG) (NN antibody))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (NN SC-2020))
                  (: ;)
                  (NP (NNP Santa) (NNP Cruz) (NN Biotechnology)))
                (-RRB- -RRB-)))
            (PRN (-LRB- -LRB-)
              (NP (NN dilution) (NN 1:5000))
              (-RRB- -RRB-))))
        (PP (IN in)
          (NP (NN DPBS)))
        (PP (IN for)
          (NP
            (NP (CD 1) (NN hour))
            (PP (IN at)
              (NP (JJ room) (NN temperature)))))))
    (. .)))

(
  (S
    (S
      (PP (IN After)
        (S
          (VP (VBG washing)
            (NP (CD three) (NNS times))
            (PP (IN in)
              (NP (NN DPBS))))))
      (, ,)
      (NP (DT the) (NNS bands))
      (VP (VBD were)
        (VP (VBN detected)
          (S
            (VP (VBG using)
              (NP
                (NP (DT the) (VBN enhanced) (NN chemiluminescence) (NN system))
                (PRN (-LRB- -LRB-)
                  (NP (NNP Amersham) (NNP Italia))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Double-stranded) (NNS oligonucleotides))
        (VP (VBG corresponding)
          (PP (TO to)
            (NP (DT the)
              (ADJP
                (ADJP (JJ wild-type))
                (CC and)
                (ADJP (VBN mutated)))
              (NP
                (NP (NN NF-κB) (NN consensus) (NN element))
                (PRN (-LRB- -LRB-)
                  (NP (NNP Santa) (NNP Cruz) (NN Biotechnology))
                  (-RRB- -RRB-)))))))
      (VP (VBD were)
        (VP (VBN used)
          (PP
            (PP (IN as)
              (NP (JJ 32P-labelled) (NNS probes)))
            (CC or)
            (PP (IN as)
              (NP
                (NP (JJ unlabelled) (NNS competitors))
                (PRN (-LRB- -LRB-)
                  (NP (CD 100) (NNS times))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NNS assays))
      (VP (VBD were)
        (VP (VBN performed)
          (PP (IN in)
            (NP
              (NP (DT a) (JJ final) (NN volume))
              (PP (IN of)
                (NP
                  (NP (CD 20) (NN μl))
                  (VP (VBG containing)
                    (NP
                      (NP
                        (NP
                          (ADJP (CD 10) (NN mM))
                          (NN Tris-HCl))
                        (PRN (-LRB- -LRB-)
                          (NP (NN pH) (CD 7.5))
                          (-RRB- -RRB-)))
                      (, ,)
                      (NP
                        (ADJP (CD 50) (NN mM))
                        (NN NaCl))
                      (, ,)
                      (NP
                        (ADJP (CD 1) (NN mM))
                        (NN dithiothreitol))
                      (, ,)
                      (NP
                        (ADJP (CD 1) (NN mM))
                        (NN ethylenediamine) (JJ tetraacetic) (NN acid))
                      (CC and)
                      (NP
                        (ADJP (CD 10) (NN %))
                        (NN glycerol)))))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Briefly))
      (, ,)
      (NP
        (NP (CD 7) (NN μg) (NN cell) (JJ nuclear) (NNS extracts))
        (, ,)
        (UCP
          (ADJP (JJ unstimulated))
          (CC or)
          (VP (VBN stimulated)
            (PP (IN with)
              (NP
                (NP (NN testosterone))
                (CC and)
                (NP (NN E2))))
            (PP (IN as)
              (ADJP (RB previously) (VBN described)))))
        (, ,))
      (VP (VBD were)
        (VP (VBN pre-incubated)
          (PP (IN with)
            (NP
              (NP
                (NP
                  (ADJP (CD 4) (NN μg))
                  (NN poly))
                (PRN (-LRB- -LRB-)
                  (NP (NN dI-dC))
                  (-RRB- -RRB-)))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (NNP Pharmacia))
                  (, ,)
                  (NP (NNP Milan) (, ,) (NNP Italy)))
                (-RRB- -RRB-))))
          (PP (IN as)
            (NP (DT a) (JJ non-specific) (NN competitor)))
          (, ,)
          (PP (IN for)
            (NP
              (NP (CD 10) (NN min))
              (PP (IN at)
                (NP (JJ room) (NN temperature))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ End-labelled) (NNS oligonucleotides))
        (PRN (-LRB- -LRB-)
          (NP
            (NP (CD 10) (NN fmol))
            (, ,)
            (NP
              (QP (RB about) (CD 30,000))
              (NN cpm)))
          (-RRB- -RRB-)))
      (VP
        (VP (VBD were)
          (ADVP (RB then))
          (VP (VBN added)
            (PP (TO to)
              (NP (DT each) (NN mixture)))
            (PP (TO to)
              (NP
                (NP (DT a) (JJ final) (NN volume))
                (PP (IN of)
                  (NP (CD 20) (NN μl)))))))
        (CC and)
        (VP (VBD were)
          (VP (VBN incubated)
            (PP (IN for)
              (NP (DT an) (JJ additional) (CD 20) (NN min)))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (JJ bound/retarded) (NNS complexes))
      (VP
        (VP (VBD were)
          (VP (VBN separated)
            (PP (IN from)
              (NP (DT the) (JJ free) (NN probe)))
            (PP (IN by)
              (NP (NN electrophoresis)))
            (PP (IN on)
              (NP
                (ADJP (CD 5) (NN %))
                (NN polyacrylamide) (NNS gels)))))
        (CC and)
        (VP (VBD were)
          (VP (VBN visualized)
            (PP (IN by)
              (NP
                (NP (NN autoradiography))
                (PP (IN of)
                  (NP (DT the) (JJ dried) (NNS gels)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT A) (NNP lane))
        (PP (IN without)
          (NP (JJ nuclear) (NN extract))))
      (VP (VBD was)
        (ADVP (RB also))
        (VP (VBN included)
          (PP (IN as)
            (NP (DT the) (JJ negative) (NN control))))))
    (. .)))

(
  (S
    (S
      (NP (NN Competition) (NNS experiments))
      (VP (VBD were)
        (VP (VBN performed)
          (PP (IN in)
            (NP
              (NP (DT the) (NN presence))
              (PP (IN of)
                (NP
                  (NP (DT a)
                    (ADJP (RB 100-fold) (JJ molar))
                    (NN excess))
                  (PP (IN of)
                    (NP
                      (NP (JJ unlabelled) (NN wall-type))
                      (CC or)
                      (NP (VBN mutated) (JJ NF-κB) (NN oligonucleotide))))
                  (, ,)
                  (VP (VBN added)
                    (PP (TO to)
                      (NP (DT the) (NN pre-incubation) (NN step)))))))))))
    (. .)))

(
  (S
    (PP (IN For)
      (NP (DT the) (JJ super) (NN shift) (NN assay)))
    (, ,)
    (NP
      (NP (CD 2) (NN μl) (JJ anti-p65))
      (, ,)
      (NP
        (NP
          (NP (NN c-rel))
          (CC and)
          (NP (NN p50))
          (NP (NN NF-κB) (NN subunit) (NNS antibodies)))
        (PRN (-LRB- -LRB-)
          (NP (NNP Santa) (NNP Cruz) (NN Biotechnology))
          (-RRB- -RRB-))))
    (VP (VBD were)
      (VP (VBN included)
        (PP (IN in)
          (NP
            (NP (DT the) (NN pre-incubation) (NN mixture))
            (ADJP (JJ prior)
              (PP (TO to)
                (NP
                  (NP (DT the) (NN addition))
                  (PP (IN of)
                    (NP (DT the) (NN probe))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT A) (NNP lane))
        (VP (VBG containing)
          (NP (NN pre-immune) (NN serum))))
      (VP (VBD was)
        (ADVP (RB always))
        (VP (VBN included)
          (PP (IN as)
            (NP (DT the) (NN control))))))
    (. .)))

(
  (S
    (NP (NNS Results))))

(
  (S
    (S
      (SBAR (IN As)
        (S
          (ADVP (RB already))
          (VP (VBN stated))))
      (, ,)
      (NP (JJ hormonal) (NNS signals))
      (VP (VBP regulate)
        (NP
          (NP (DT the) (NN amount))
          (PP
            (PP (IN of)
              (NP (DT the) (JJ cell-cycle) (NN control) (NNS proteins)))
            (CC and)
            (PP (IN of)
              (NP (DT the) (NN transcription) (NNS factors)
                (NP (CD -LSB-26)))))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (DT the) (JJ present) (NN study)))
      (, ,)
      (PP (IN after)
        (NP (CD 168) (NNS hours)))
      (NP (PRP we))
      (VP (VBD observed)
        (NP
          (NP (DT a) (JJ significant) (NN growth) (NN inhibition))
          (PP (IN of)
            (NP
              (NP (DT the) (JJ human) (JJ monocytic) (NN cell) (NN line))
              (VP
                (VP (VBN activated)
                  (PP (IN with)
                    (NP (NN IFN-γ))))
                (CC and)
                (VP (VBN treated)
                  (PP (IN with)
                    (NP (NN testosterone)))))))
          (, ,)
          (SBAR
            (WHADVP (WRB when))
            (S
              (VP (VBN compared)
                (PP (IN with)
                  (NP
                    (NP (DT the) (JJ other) (NNS conditions))
                    (VP (VBN studied))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN At)
        (NP (CD 168) (NNS hours)))
      (NP (DT the) (NN cell) (NN growth))
      (VP (VBD was)
        (VP (VBN reduced)
          (PP
            (PP (IN by)
              (NP
                (NP (CD 14.8) (NN %))
                (CC versus)
                (NP (JJ untreated) (NNS controls))))
            (CC and)
            (PP (IN by)
              (NP
                (NP (CD 12.7) (NN %))
                (CC versus)
                (NP (JJ E2-treated) (NNS cells))))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS data))
      (VP (VBD were)
        (VP
          (VP (VBN obtained)
            (PP (IN with)
              (NP (DT the) (NN methyl-tetrazolium) (NN salt) (NN test))))
          (CC and)
          (VP (VBN confirmed)
            (PP (IN with)
              (NP
                (NP (DT the) (NN trypan) (JJ blue) (NN exclusion) (NN assay))
                (PRN (-LRB- -LRB-)
                  (NP (NNP Fig.) (CD 1))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (JJ bromodeoxyuridine/propidium) (NN iodide) (NN incorporation) (NN test))
      (VP (VBD showed)
        (NP (JJ similar) (NNS results))
        (PRN (-LRB- -LRB-)
          (S
            (NP (NNS data))
            (VP (RB not) (VBN shown)))
          (-RRB- -RRB-))))
    (. .)))

(
  (S
    (S
      (NP (JJ Further) (JJ interesting) (NNS data))
      (VP (VBD were)
        (ADJP (JJ related)
          (PP (TO to)
            (NP
              (NP (DT the) (NN modulation))
              (PP (IN of)
                (NP (DT the) (NN PCNA) (NN expression))))))
        (, ,)
        (PP (IN as)
          (NP
            (NP (DT a) (NN marker))
            (PP (IN for)
              (NP (VBG proliferating) (NNS cells)))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (DT This) (NN marker))
        (VP (VBD was)
          (VP (VBN analysed)
            (PP (IN by)
              (NP (NN immunocytochemistry))))))
      (CC and)
      (S
        (NP (DT the) (NNS data))
        (VP (VBD were)
          (VP (VBN confirmed)
            (PP (IN by)
              (NP (NN western) (NN blot) (NN analysis)))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP (DT the) (JJ testosterone-treated) (NNS cells)))
    (, ,)
    (NP
      (NP (DT the) (NN expression))
      (PP (IN of)
        (NP (DT the) (NN PCNA)))
      (PP (IN at)
        (NP (DT the) (NN immunocytochemistry) (NN analysis))))
    (VP
      (VP (VBD was)
        (VP (VBN found)
          (PP (VBN decreased)
            (PP (IN by)
              (NP (CD 24) (NN %)))))
        (SBAR
          (WHADVP (WRB when))
          (S
            (VP (VBN compared)
              (PP (IN with)
                (NP (JJ untreated) (NNS cells)))))))
      (, ,)
      (CC and)
      (VP (VBD was)
        (VP (VBN decreased)
          (PP (IN by)
            (NP (CD 40) (NN %))))
        (SBAR
          (WHADVP (WRB when))
          (S
            (VP (VBN compared)
              (PP (IN with)
                (NP
                  (NP (JJ E2-treated) (NNS cells))
                  (PRN (-LRB- -LRB-)
                    (NP (NNP Fig.) (NNP 2a–d))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (ADVP (RB Interestingly))
    (, ,)
    (NP (DT the) (JJ testosterone-treated) (NNS cells))
    (VP (VBD showed)
      (NP (NN staining) (NN positivity))
      (VP (VBD localized)
        (PP (IN in)
          (NP (DT the) (NN cell) (NN cytoplasm)))
        (, ,)
        (SBAR (IN whereas)
          (S
            (PP (IN in)
              (NP (DT the)
                (ADJP
                  (ADJP (JJ untreated))
                  (CC and)
                  (ADJP (JJ E2-treated)))
                (NNS cells)))
            (NP (DT the) (NN PCNA) (NN expression))
            (VP (VBD was)
              (VP (VBN found)
                (ADVP (RB predominantly))
                (PP (IN in)
                  (NP (DT the) (NN nucleus)))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (DT the) (JJ present) (NN study)))
      (NP
        (NP
          (NP (DT the) (JJ inhibitory) (NN role))
          (PP (IN of)
            (NP (NN E2)))
          (PP (IN on)
            (NP (NN apoptosis))))
        (, ,)
        (CONJP (RB as) (RB well) (IN as))
        (NP
          (NP (DT the) (JJ pro-apoptotic) (NNS effects))
          (VP (VBN exerted)
            (PP (IN by)
              (NP (NN testosterone)))
            (PP (IN in)
              (NP
                (NP (JJ long-term) (NN treatment))
                (PP (IN of)
                  (NP (NN THP-1) (NNS cells)))))))
        (, ,))
      (VP (VBD were)
        (VP (VBN investigated))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN annexin) (NN V-propidium) (NN iodide) (NN analysis))
      (VP (VBD showed)
        (NP
          (NP (DT a) (JJ significant) (NN increase))
          (PP (IN of)
            (NP
              (ADJP
                (ADJP (JJ early))
                (CC and)
                (ADJP (JJ late)))
              (NN apoptosis)))
          (PP (IN in)
            (NP (JJ testosterone-treated) (NNS cells))))
        (SBAR
          (WHADVP (WRB when))
          (S
            (VP (VBN compared)
              (PP (IN with)
                (NP (JJ other) (NNS conditions))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP
          (NP (DT the) (NN absence))
          (PP (IN of)
            (NP (NN staurosporine)))))
      (, ,)
      (NP (DT the) (NN apoptosis))
      (VP (VBD was)
        (VP (VBN found)
          (VP (VBN increased)
            (PP (IN in)
              (NP
                (NP (JJ testosterone-treated) (NNS cells))
                (PRN (-LRB- -LRB-)
                  (NP (CD 9.9) (NN %))
                  (-RRB- -RRB-))))
            (SBAR
              (WHADVP (WRB when))
              (S
                (VP (VBN compared)
                  (PP
                    (PP (IN with)
                      (NP
                        (NP (JJ control) (JJ untreated) (NNS cells))
                        (PRN (-LRB- -LRB-)
                          (NP (CD 2.7) (NN %))
                          (-RRB- -RRB-))))
                    (CC and)
                    (PP (IN with)
                      (NP
                        (NP (JJ E2-treated) (NNS cells))
                        (PRN (-LRB- -LRB-)
                          (NP (CD 3.8) (NN %))
                          (-RRB- -RRB-))))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In) (DT the) (NN presence) (IN of)
        (NP (NN staurosporine)))
      (, ,)
      (NP (DT the) (JJ apoptotic) (NNS cells))
      (VP (VBD were)
        (VP (VBN increased)
          (PP (IN in)
            (NP (DT all) (NNS conditions))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP
          (NP (JJ testosterone-treated) (NNS cells))
          (PRN (-LRB- -LRB-)
            (NP (CD 24.8) (NN %))
            (-RRB- -RRB-))))
      (NP (DT the) (NN apoptosis))
      (VP (VBD was)
        (VP (VBN found)
          (VP (VBN increased)
            (SBAR
              (WHADVP (WRB when))
              (S
                (VP (VBN compared)
                  (PP (IN with)
                    (NP
                      (NP (JJ untreated) (NNS cells))
                      (PRN (-LRB- -LRB-)
                        (NP (CD 19.4) (NN %))
                        (-RRB- -RRB-)))))))))))
    (. .)))

(
  (S
    (PP (IN On)
      (NP (DT the) (NN contrary)))
    (, ,)
    (PP (IN in)
      (NP (DT the)
        (ADJP
          (ADJP (JJ E2-treated))
          (PRN (-LRB- -LRB-)
            (NP (CD 15) (NN %))
            (-RRB- -RRB-)))
        (NNS cells)))
    (NP (DT the) (NN apoptosis))
    (VP (VBD was)
      (NP
        (NP (VBN decreased))
        (CC versus)
        (NP
          (NP
            (NP (NNS controls))
            (PRN (-LRB- -LRB-)
              (NP (CD 19.4) (NN %))
              (-RRB- -RRB-)))
          (PRN (-LRB- -LRB-)
            (NP (NNP Fig.) (NN 3a))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS data))
      (VP (VBD were)
        (VP (VBN confirmed)
          (PP (IN by)
            (NP
              (NP (NN flow) (NN analysis) (NN cytometry) (NN scatter) (NN analysis))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP
                    (NP (NNP Fig.))
                    (NP (NN 3b)))
                  (, ,)
                  (NP (NN c)))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN immunocytochemistry) (NN analysis))
      (VP (VBD showed)
        (NP
          (NP (DT a) (JJ significant) (NN increase))
          (PP (IN of)
            (NP (DT the) (JJ PARP-cleaved) (NN form)))
          (PP (IN in)
            (NP (JJ testosterone-treated) (NNS cells))))
        (PP (VBN compared)
          (PP (IN with)
            (NP (JJ other) (NNS conditions))))
        (, ,)
        (S
          (VP (VBG suggesting)
            (NP
              (NP (DT an) (NN increase))
              (PP (IN of)
                (NP (JJ pro-apoptotic) (NNS events))))))))
    (. .)))

(
  (S
    (PP (IN On)
      (NP (DT the) (NN contrary)))
    (, ,)
    (NP (DT the) (JJ PARP-cleaved) (NN staining))
    (VP (VBD showed)
      (NP
        (NP (DT a) (NN decrease))
        (PRN (-LRB- -LRB-)
          (NP
            (NP (CD 19) (NN %))
            (CC versus)
            (NP (JJ untreated) (NNS controls)))
          (-RRB- -RRB-)))
      (PP (IN in)
        (NP (JJ E2-treated) (NNS cells)))
      (, ,)
      (S
        (VP (VBG suggesting)
          (NP
            (NP (DT a) (NN trend))
            (PP (IN of)
              (NP (NNS oestrogens)))
            (PP (IN in)
              (S
                (VP (VBG protecting)
                  (NP (NNS cells))
                  (PP (IN from)
                    (NP (DT the) (JJ apoptotic) (NNS stimuli))))))))))
    (PRN (-LRB- -LRB-)
      (NP (NNP Fig.) (CD 4a–e))
      (-RRB- -RRB-))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS data))
      (VP (VBD were)
        (VP (VBN confirmed)
          (PP (IN with)
            (NP (NN western) (NN blot) (NN analysis))))))
    (. .)))

(
  (S
    (NP
      (NP (DT The) (VBN defined) (NN mechanism))
      (PP (IN of)
        (NP (NN NF-κB) (NN activation))))
    (VP (VBZ includes)
      (NP
        (NP (DT the)
          (NP (JJ site-specific) (NN phosphorylation))
          (CC and)
          (NP (JJ subsequent) (NN degradation)))
        (PP (IN of)
          (NP
            (NP (DT the) (JJ inhibitory) (NN IκB-α) (NN factor))
            (, ,)
            (SBAR
              (WHNP (WDT which))
              (S
                (ADVP (RB usually))
                (VP (VBZ retains)
                  (NP
                    (NP (DT the) (JJ NF-κB) (NNS factors))
                    (VP (VBN inactivated)
                      (PP (IN in)
                        (NP (NN cytosol) (CD -LSB-27))))))
                (-RRB- -RSB-)))))))
    (. .)))

(
  (S
    (NP (PRP We))
    (ADVP (RB therefore))
    (VP (VBD performed)
      (NP (NN western) (NN blot) (NN analysis))
      (S
        (VP (TO to)
          (VP (VB detect)
            (NP
              (NP (DT the) (NN expression))
              (PP (IN of)
                (NP
                  (NP
                    (NP (NN NF-κB))
                    (PRN (-LRB- -LRB-)
                      (NP (NN p65))
                      (-RRB- -RRB-)))
                  (, ,)
                  (NP (NN IκB-α))
                  (CC and)
                  (NP
                    (NP (DT the) (JJ IκB-α) (JJ phosphorylated) (NN form))
                    (PRN (-LRB- -LRB-)
                      (NP (NN IκB-α-ser) (CD 32))
                      (-RRB- -RRB-)))))
              (PP (IN in)
                (NP
                  (NP (NN THP-1) (NNS cells))
                  (VP (VBN treated)
                    (PP (IN with)
                      (NP (DT the) (JJ different) (NN hormone) (NNS combinations)))))))))))
    (. .)))

(
  (S
    (S
      (SBAR (IN As)
        (S
          (VP (VBN shown)
            (PP (IN in)
              (NP
                (NP
                  (NP (NN western) (NN blot) (NN analysis))
                  (PRN (-LRB- -LRB-)
                    (NP (NNP Fig.) (CD 5))
                    (-RRB- -RRB-)))
                (NP
                  (NP
                    (NP (DT a) (VBN decreased) (NN expression))
                    (PP (IN of)
                      (NP
                        (NP (NN NF-κB))
                        (PRN (-LRB- -LRB-)
                          (NP (NN p65))
                          (-RRB- -RRB-)))))
                  (CC and)
                  (NP
                    (NP (DT an) (VBN increased) (NN content))
                    (PP (IN of)
                      (NP (NN IκB-α)))
                    (PP (IN with)
                      (NP
                        (NP (DT a) (JJ concomitant) (NN decrease))
                        (PP (IN of)
                          (NP (DT the) (JJ IκB-α) (JJ phosphorylated) (NN form))))))))))))
      (VP (VBD was)
        (VP (VBN observed)
          (PP (IN in)
            (NP (JJ testosterone-treated) (NNS cells)))
          (SBAR
            (WHADVP (WRB when))
            (S
              (VP (VBN compared)
                (PP
                  (PP (IN with)
                    (NP (JJ untreated) (NNS controls)))
                  (CC and)
                  (PP (IN with)
                    (NP (JJ E2-treated) (NN THP-1) (NNS cells))))))))))
    (: ;)
    (S
      (NP
        (NP (DT the) (NNS differences))
        (PP (IN between)
          (NP
            (NP (NNS conditions))
            (VP (VBN observed)
              (PP (IN with)
                (NP (NN staurosporine) (NN treatment)))))))
      (VP (VBD were)
        (ADJP (JJ similar))))
    (CC but)
    (S
      (NP (DT the) (NN expression))
      (VP (VBD was)
        (ADJP (JJR lower))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (VBN observed) (NNS differences))
        (PP (IN between)
          (NP
            (ADJP
              (ADJP (JJ E2-treated))
              (CC and)
              (ADJP (JJ testosterone-treated)))
            (NN THP-1) (NNS cells))))
      (VP (VBD were)
        (VP (VBN confirmed)
          (PP (IN by)
            (NP
              (NP (NN immunocytochemistry) (NN staining))
              (CC and)
              (NP (NN image) (NN analysis)))))))
    (: ;)
    (S
      (NP (JJ similar) (NNS data))
      (VP (VBD were)
        (VP (VBN observed)
          (PP (IN with)
            (NP
              (NP (NN staurosporine) (NN treatment))
              (PRN (-LRB- -LRB-)
                (NP (NN Table) (CD 1))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP (DT The) (JJ concomitant) (JJ electrophoretic) (NN mobility) (NN shift) (NN assay))
          (NN analysis))
        (PP (IN for)
          (NP
            (NP (DT the) (NN evaluation))
            (PP (IN of)
              (NP (DT the) (JJ NF-κB) (NN DNA) (NN binding))))))
      (VP (VBD confirmed)
        (NP (DT an) (VBN increased) (NN binding))
        (PP (IN in)
          (NP (JJ E2-treated) (NNS cells)))
        (, ,)
        (SBAR
          (WHADVP (WRB when))
          (S
            (VP (VBN compared)
              (PP (IN with)
                (NP
                  (NP (JJ other) (NNS conditions))
                  (PP (IN with)
                    (CC or)
                    (PP (IN without)
                      (NP (NN staurosporine))))))
              (, ,)
              (SBAR (IN as)
                (S
                  (VP (VBN shown)
                    (PP (IN in)
                      (NP (NNP Fig.) (CD 6a)))))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Finally))
      (, ,)
      (NP
        (NP (DT the) (NN gel) (NN shift) (NN assay))
        (PP (IN of)
          (NP
            (NP (JJ nuclear) (NN protein) (NNS extracts))
            (PP (IN from)
              (NP (JJ E2-treated) (NNS cells))))))
      (ADVP (RB again))
      (VP (VBD showed)
        (NP
          (NP (DT an) (NN increase))
          (PP (IN of)
            (NP
              (NP (DT the) (NN p65) (NN subunit) (NN DNA) (NN binding))
              (PRN (-LRB- -LRB-)
                (NP (NNP Fig.) (CD 6b))
                (-RRB- -RRB-)))))
        (SBAR
          (WHADVP (WRB when))
          (S
            (VP (VBN compared)
              (PP (IN with)
                (NP (JJ other) (NNS conditions))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Similar) (NNS results))
      (VP (VBD were)
        (VP (VBN obtained)
          (PP (IN during)
            (NP (NN staurosporine) (NN treatment))))))
    (. .)))

(
  (S
    (NP (NN Discussion))))

(
  (S
    (S
      (NP (NNS Monocytes/macrophages))
      (VP (VBP contribute)
        (PP
          (PP (TO to)
            (NP (DT the) (JJ autoimmune) (NN process)))
          (, ,)
          (ADVP (RB mainly))
          (PP (VBG acting)
            (PP (IN as)
              (NP
                (NP (JJ antigen-processing/presenting) (NNS cells))
                (CC and)
                (NP
                  (NP (NNS sources))
                  (PP (IN of)
                    (NP (JJ inflammatory) (NNS cytokines)))))))
          (, ,)
          (ADVP (RB particularly))
          (PP (IN at)
            (NP
              (NP (DT the) (NN level))
              (PP (IN of)
                (NP (DT the) (JJ synovial) (NN tissue)))
              (PP (IN in)
                (NP (NN RA) (CD -LSB-28) (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Moreover))
      (, ,)
      (NP (NN sex) (NNS hormones))
      (VP (MD can)
        (VP (VB exert)
          (NP
            (NP (JJ local) (NNS actions))
            (PRN (-LRB- -LRB-)
              (NP (NN paracrine))
              (-RRB- -RRB-)))
          (PP (IN in)
            (NP
              (NP (DT the) (NNS tissues))
              (SBAR
                (WHPP (IN in)
                  (WHNP (WDT which)))
                (S
                  (NP (PRP they))
                  (VP (VBP are)
                    (VP (VBN formed)))))
              (, ,)
              (PP (VBG including)
                (NP (DT the) (JJ synovial) (NN tissue) (NN -LSB-29,30)))))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (NP (VBN Activated) (NN THP-1) (NNS cells))
      (VP (VBP differentiate)
        (PP (IN into)
          (NP
            (NP (NNS macrophages))
            (PP (IN for)
              (NP (JJ long-term) (NNS cultures)))))))
    (. .)))

(
  (S
    (S
      (PP (IN On)
        (NP (DT the) (NN contrary)))
      (, ,)
      (NP (JJ synovial) (NNS macrophages))
      (VP (VBP are)
        (VP (VBN characterized)
          (PP (IN by)
            (NP
              (NP (DT a) (JJ short) (NN life))
              (PP (IN during)
                (NP
                  (ADJP (FW in) (FW vitro))
                  (NN culture))))))))
    (. .)))

(
  (S
    (NP (DT The) (JJ present) (NN study))
    (VP (VBZ shows)
      (NP
        (NP (JJ opposite) (NNS effects))
        (PP (IN by)
          (NP (NN sex) (NNS hormones)))
        (PP (IN on)
          (NP
            (NP (NNS cultures))
            (PP (IN of)
              (NP
                (NP
                  (NP (VBN activated) (NN monocytic/macrophage) (NNS cells))
                  (PRN (-LRB- -LRB-)
                    (NP (NN THP-1) (NNS cells))
                    (-RRB- -RRB-)))
                (VP (VBG concerning)
                  (NP
                    (NP (PRP$ their) (JJ modulatory) (NNS effects))
                    (PP (IN on)
                      (NP (NN cell)
                        (NP (NN proliferation))
                        (CC and/or)
                        (NP (NN apoptosis))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN signalling) (NNS pathways))
        (PP (VBG modulating)
          (NP (DT the)
            (ADJP
              (ADJP (JJ pro-inflammatory))
              (CC and)
              (ADJP (JJ anti-inflammatory)))
            (NNS mechanisms))))
      (VP (VBP seem)
        (S
          (VP (TO to)
            (VP (VB involve)
              (NP (JJ steroidal) (NN hormone) (NN receptor) (NN activation)))))))
    (CC and)
    (S
      (NP (DT the) (JJ NF-κB) (NN complex) (NNS factors))
      (, ,)
      (PP (IN In)
        (NP (NN addition)))
      (, ,)
      (NP (NNS oestrogens))
      (VP (MD may)
        (ADVP (RB differently))
        (VP (VB regulate)
          (NP (NN NF-κB) (NN activation))
          (PP (VBG depending)
            (PP (IN on)
              (NP
                (NP (DT the) (NN cell) (NN type))
                (VP (VBN tested)
                  (S
                    (NP (NN -LSB-14,31)))))))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (NP (NN E2))
      (ADVP (RB therefore))
      (VP (VBD increased)
        (NP
          (NP (DT the) (NN expression))
          (PP (IN of)
            (NP
              (NP (NNS markers))
              (PP (IN of)
                (NP (NN cell)
                  (NP (NN growth))
                  (CC and)
                  (NP (NN proliferation)))))))
        (, ,)
        (SBAR (IN whereas)
          (S
            (NP (NN testosterone))
            (VP (VBD induced)
              (NP
                (NP (DT an) (NN increase))
                (PP (IN of)
                  (NP (DT the) (JJ PARP-cleaved) (NN expression)))))))
        (, ,)
        (S
          (VP (VBG indicating)
            (NP
              (NP (NN DNA) (NN damage))
              (CC and)
              (NP (NN apoptosis)))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN addition)))
      (, ,)
      (S
        (VP (TO to)
          (VP (VB support)
            (NP
              (NP (DT the) (JJ proliferative) (NN role))
              (VP (VBN exerted)
                (PP (IN by)
                  (NP (NN E2))))))))
      (, ,)
      (NP
        (NP (DT the) (NN THP-1) (NNS cells))
        (VP (VBN pre-treated)
          (PP (IN with)
            (NP (DT the) (NNS oestrogens)))))
      (VP (VBD showed)
        (NP
          (NP (DT a) (NN decrease))
          (PP (IN of)
            (NP (JJ staurosporine-induced) (NN apoptosis))))
        (SBAR
          (WHADVP (WRB when))
          (S
            (VP (VBN compared)
              (PP (IN with)
                (NP
                  (ADJP
                    (ADJP (JJ testosterone-treated))
                    (CC and)
                    (ADJP (JJ untreated)))
                  (NNS cells))))))))
    (. .)))

(
  (S
    (ADVP (RB Furthermore))
    (, ,)
    (NP
      (NP
        (NP
          (NP (DT the) (VBN increased) (NN NF-κB) (NN p65) (NN expression))
          (CC and)
          (NP
            (NP (DT the) (JJ evident) (NN NF-κB) (NN binding))
            (PP (TO to)
              (NP (NN DNA)))))
        (PP (IN in)
          (NP
            (NP (JJ E2-treated) (NNS cells))
            (, ,)
            (SBAR
              (WHADVP (WRB when))
              (S
                (VP (VBN compared)
                  (PP
                    (PP (IN with)
                      (NP (JJ untreated) (NNS cells)))
                    (CC or)
                    (PP (IN with)
                      (NP (JJ testosterone-treated) (NNS cells))))))))))
      (, ,)
      (CONJP (RB as) (RB well) (IN as))
      (NP
        (NP (DT the) (VBN increased) (NNS levels))
        (PP (IN of)
          (NP (DT the) (JJ IκB-α) (JJ phosphorylated) (NN form))))
      (, ,))
    (VP (VBZ seems)
      (S
        (VP (TO to)
          (VP (VB support)
            (NP
              (NP (DT the) (JJ major) (JJ enhancing) (NN role))
              (VP (VBN exerted)
                (PP (IN by)
                  (NP (NNS oestrogens)))
                (PP (IN on)
                  (NP (DT the) (JJ immune/inflammatory) (NN response)))
                (PP (IN by)
                  (S
                    (VP (VBG activating)
                      (NP (DT the) (JJ NF-κB) (NN complex)))))))))))
    (. .)))

(
  (S
    (PP (IN On)
      (NP (DT the) (NN contrary)))
    (, ,)
    (NP
      (NP (DT the) (VBN observed) (JJ positive) (NN upregulation))
      (PP (IN of)
        (NP
          (NP (NN IκB-α))
          (VP (VBN exerted)
            (PP (IN by)
              (NP (NN testosterone) (NN treatment)))))))
    (ADVP (RB presumably))
    (VP
      (VP (VBZ dampens)
        (NP
          (NP (DT the) (JJ pro-inflammatory) (NNS effects))
          (VP (VBN mediated)
            (PP (IN by)
              (NP (DT the) (JJ NF-κB) (NN activation))))))
      (, ,)
      (CC and)
      (ADVP (RB therefore))
      (VP (MD might)
        (VP (VB represent)
          (NP
            (NP (DT a) (JJ further) (NN mechanism))
            (SBAR
              (WHPP (IN by)
                (WHNP (WDT which)))
              (S
                (NP (NNS androgens))
                (VP (VBP exert)
                  (NP (JJ anti-inflammatory) (NNS effects)))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ Recent) (NNS studies))
      (VP (VBP support)
        (NP (DT these) (NNS results))
        (, ,)
        (S
          (VP (VBG showing)
            (SBAR (IN that)
              (S
                (NP (NN E2))
                (VP (VBZ inhibits)
                  (NP
                    (NP (NN apoptosis))
                    (PP (IN in)
                      (NP
                        (NP (JJ different) (NN cell) (NNS types))
                        (PRN (-LRB- -LRB-)
                          (NP
                            (NP (JJ cardiac) (NNS myocytes))
                            (CC and)
                            (NP (NNS others)))
                          (-RRB- -RRB-)))))
                  (SBAR (IN whereas)
                    (S
                      (NP (NNS androgens))
                      (VP (VBP have)
                        (VP (VBN been)
                          (VP (VBN found)
                            (S
                              (VP (TO to)
                                (VP (VB induce)
                                  (NP (NN apoptosis) (CD -LSB-32,33) (-RRB- -RSB-)))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (VBN increased) (NNS concentrations))
        (PP (IN of)
          (NP
            (NP
              (NP (NNS oestrogens))
              (-LRB- -LRB-)
              (CC and)
              (NP (JJ low) (NNS androgens))
              (-RRB- -RRB-))
            (VP
              (ADVP (RB recently))
              (VBN described)
              (PP (IN at)
                (NP
                  (NP (DT the) (NN level))
                  (PP (IN of)
                    (NP
                      (NP (DT the) (JJ synovial) (NN fluid))
                      (PP (IN of)
                        (NP (NN RA) (NNS patients))))))))))
        (PP (IN of)
          (NP (DT both) (NNS sexes)
            (NP (CD -LSB-29))))
        (-RRB- -RSB-))
      (VP (VBP seem)
        (S
          (VP (TO to)
            (VP (VB support)
              (NP (PRP$ their) (JJ possible) (NN modulator) (NNS roles))
              (PP (IN on)
                (NP
                  (NP (JJ synovial) (NN tissue) (NN hyperplasia))
                  (CC and)
                  (NP (JJ chronic) (JJ synovial) (NN cell) (NN activation))))
              (, ,)
              (PP (IN by)
                (S
                  (VP (VBG considering)
                    (NP
                      (NP (DT the) (JJ oestrogenic) (NNS effects))
                      (PP (IN on)
                        (NP
                          (NP (NN cell) (NN proliferation))
                          (CC and)
                          (NP (NN apoptosis)))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS observations))
      (VP (VBP have)
        (VP (VBN been)
          (ADVP (RB recently))
          (VP (VBN obtained)
            (PP
              (ADVP (RB also))
              (IN in)
              (NP (JJ human) (NN breast) (NN cancer) (NNS cells)))
            (NP (CD -LSB-34))
            (-RRB- -RSB-)))))
    (. .)))

(
  (S
    (S
      (S
        (VP (TO To)
          (VP (VB explain)
            (NP
              (NP (VBN increased) (NN oestrogen) (NNS concentrations))
              (PP (IN in)
                (NP (NN RA) (JJ synovial) (NNS fluids)))))))
      (, ,)
      (S
        (NP
          (NP (DT the) (JJ pro-inflammatory) (NNS cytokines))
          (PRN (-LRB- -LRB-)
            (NP
              (NP (NN tumour) (NN necrosis) (NN factor) (NN alpha))
              (, ,)
              (NP (NN IL-1β))
              (, ,)
              (NP (NN IL-6)))
            (-RRB- -RRB-)))
        (VP (VBP have)
          (VP (VBN been)
            (VP (VBN found)
              (S
                (VP (TO to)
                  (VP (VB accelerate)
                    (NP
                      (NP (DT the) (JJ metabolic) (NN conversion))
                      (PP (IN of)
                        (NP (NNS oestrogens)))
                      (PP (IN from)
                        (NP (NNS androgens))))
                    (PP (IN by)
                      (S
                        (VP (VBG inducing)
                          (NP
                            (NP (DT the) (JJ synovial) (NN tissue) (NNS aromatases))
                            (CD -LSB-35-37) (-RRB- -RSB-)))))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN As)
        (NP (DT a) (NN consequence)))
      (, ,)
      (NP
        (ADJP (RB locally) (VBN increased))
        (NN oestrogen) (NNS levels))
      (VP (MD might)
        (VP (VB exert)
          (NP
            (NP (JJ activating) (NNS effects))
            (PP (IN on)
              (NP (JJ synovial) (NN cell) (NN proliferation)))
            (, ,)
            (PP (VBG including)
              (NP
                (NP (NNS macrophages))
                (CC and)
                (NP (NNS fibroblasts) (CD -LSB-38) (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (NP (NN Conclusion))))

(
  (S
    (PP (IN In)
      (NP (DT the) (JJ present) (NN study)))
    (NP
      (NP (DT the) (NNS concentrations))
      (PP (IN for)
        (NP
          (NP (NN E2))
          (CC and)
          (NP (NN testosterone)))))
    (VP (VBD tested)
      (VP (VB seem)
        (S
          (VP (TO to)
            (VP (VB modulate)
              (NP
                (NP (DT the) (NN activity))
                (PP (IN of)
                  (NP (JJ NF-κB) (NNS molecules)))
                (PP (IN in)
                  (NP
                    (NP
                      (NP (DT the) (JJ human) (NN monocytic/macrophage) (NN cell) (NN line))
                      (PRN (-LRB- -LRB-)
                        (NP (NN THP-1))
                        (-RRB- -RRB-)))
                    (PP (IN with)
                      (NP (JJ opposite) (NNS effects))))))))))
      (, ,)
      (S
        (VP (VBG interfering)
          (PP (IN with)
            (NP (NN cell)
              (NP
                (NP (NN growth))
                (CC and)
                (NP (NN apoptosis))))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS observations))
      (VP (MD might)
        (VP (VBP provide)
          (NP
            (NP (DT a) (JJ further) (JJ biological) (NN link))
            (PP (IN between)
              (NP
                (NP (NN gender) (NNS effects))
                (CC and)
                (NP
                  (NP (DT the) (JJ complex) (JJ inflammatory) (NN process))
                  (VP (VBN involved)
                    (PP (IN in)
                      (NP (JJ rheumatoid) (NN synovitis)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Further) (NNS studies))
        (, ,)
        (VP (VBG using)
          (NP
            (NP
              (NP (JJ peripheral) (NNS metabolites))
              (PP (IN of)
                (NP (NNS oestrogens))))
            (CC and)
            (NP
              (NP (JJ synovial) (NNS macrophages))
              (PP (IN from)
                (NP (NN RA) (NNS patients))))))
        (, ,))
      (VP (MD might)
        (VP (VB extend)
          (NP
            (NP (DT the) (NN value))
            (PP (IN of)
              (NP (DT these) (NNS observations)))))))
    (. .)))

(
  (S
    (NP (NNS Abbreviations))))

(
  (S
    (S
      (NP (NNS DPBS))
      (VP (VBG =)
        (NP
          (NP
            (NP (NN Dulbecco) (POS 's) (JJ phosphate-buffered) (NN saline))
            (: ;)
            (NP (NN E2) (JJ =) (NN 17β-oestradiol))
            (: ;)
            (NP
              (ADJP
                (NP
                  (NP (NN IFN) (JJ =) (NN interferon))
                  (: ;)
                  (NP (NN IL) (JJ =) (NN interleukin))
                  (: ;)
                  (NP (NN NF) (JJ =) (JJ nuclear) (NN factor))
                  (: ;)
                  (NP (NN PARP) (JJ =) (NN poly-ADP) (NN ribose) (NN polymerase))
                  (: ;)
                  (NP (NNS PBS)))
                (JJ =))
              (JJ phosphate-buffered) (NN saline))
            (: ;)
            (NP (NN PCNA) (JJ =) (JJ proliferating) (NN cell) (JJ nuclear) (NN antigen))
            (: ;)
            (NP (NN RA) (JJ =) (JJ rheumatoid) (NN arthritis))
            (: ;)
            (NP (NN THP-1)))
          (JJ =)
          (NP (VBN cultured) (JJ human) (NN monocytic/macrophage) (NN cell) (NN line)))))
    (. .)))

(
  (S
    (NP (VBG Competing) (NNS interests))))

(
  (S
    (S
      (NP (DT The) (NN author) (-LRB- -LRB-) (NNS s) (-RRB- -RRB-))
      (VP (VB declare)
        (SBAR (IN that)
          (S
            (NP (PRP they))
            (VP (VBP have)
              (NP (DT no) (VBG competing) (NNS interests)))))))
    (. .)))

(
  (S
    (NP
      (NP (NNS Authors) (POS '))
      (NNS contributions))))

(
  (S
    (S
      (NP (NN MC))
      (VP
        (VP (VBN conceived)
          (NP (DT the) (NN study)))
        (CC and)
        (VP (VBN drafted)
          (NP (DT the) (NN manuscript)))))
    (. .)))

(
  (S
    (S
      (NP (NN SC))
      (VP (VBD participated)
        (PP (IN in)
          (S
            (VP (VBG conducting)
              (NP
                (NP (NN THP-1) (NN cell) (NN growth))
                (CC and)
                (NP (DT the) (JJ functional) (NN assay))))))))
    (. .)))

(
  (S
    (S
      (NP (NN PM))
      (VP (VBN conducted)
        (NP
          (NP (DT the) (NN immunocytochemistry) (NN assay))
          (CC and)
          (NP (DT the) (NN western) (NN blot) (NN assay)))))
    (. .)))

(
  (S
    (S
      (NP (NN PG))
      (VP (VBN conducted)
        (NP
          (NP (DT the) (JJ electrophoretic) (NN mobility) (NN shift) (NN assay))
          (CC and)
          (NP (DT the) (NN super) (NN shift) (NN assay)))))
    (. .)))

(
  (S
    (S (IN AS)
      (VP (VBD helped)
        (S
          (VP (TO to)
            (VP (VB perform)
              (NP (JJ statistical) (NN analysis)))))))
    (. .)))

(
  (S
    (S
      (NP (NN BV))
      (VP
        (VP (VBD participated)
          (PP (IN in)
            (NP
              (NP (DT the) (NN study) (NN design))
              (, ,)
              (NP (NN coordination))
              (CC and)
              (NP (NN data) (NN analysis)))))
        (, ,)
        (CC and)
        (VP (VBN drafted)
          (NP (DT the) (NN manuscript)))))
    (. .)))

(
  (S
    (S
      (NP (DT All) (NNS authors))
      (VP
        (VP (VBN read))
        (CC and)
        (VP (JJ approved)
          (NP (DT the) (JJ final) (NN manuscript)))))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure))
      (CC and)
      (NP (NN Table))
      (NP (NNS captions)))))

(
  (S
    (NP
      (NP (NN Figure) (CD 1))
      (: :)
      (NP
        (NP (NN Growth) (NN rate))
        (PP (IN of)
          (NP
            (NP (DT the) (VBN cultured) (JJ human) (NN THP-1) (NN cell) (NN line))
            (PP
              (PP (IN without))
              (CC or)
              (PP (IN with)
                (NP
                  (NP
                    (NP (NN 17β-oestradiol))
                    (PRN (-LRB- -LRB-)
                      (NP (NN E2))
                      (-RRB- -RRB-)))
                  (CC and)
                  (NP
                    (NP (NN testosterone))
                    (PRN (-LRB- -LRB-)
                      (NP (NN T))
                      (-RRB- -RRB-)))))
              (, ,)
              (CC and)
              (PP (IN with)
                (NP (NN staurosporine)))
              (PP (IN after)
                (NP (CD 168) (NNS hours)))))))
      (. .))))

(
  (S
    (S
      (NP
        (NP (DT The) (NN number))
        (PP (IN of)
          (NP (VBN recovered) (JJ live) (NNS cells)))
        (PP (IN at)
          (NP (JJ different) (NNS times))))
      (VP (VBD was)
        (VP (VBN evaluated)
          (S
            (VP (VBG using)
              (NP (DT the)
                (NP (NN methyl) (NN tetrazolium) (NN salt))
                (NN reduction) (NN test)))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Results))
      (VP (VBP are)
        (VP (VBN expressed)
          (PP (IN as)
            (NP
              (NP (DT the) (NN mean) (NN ±) (JJ standard) (NN deviation))
              (PP (IN of)
                (NP (CD five) (JJ different) (NNS experiments))))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure) (CD 2))
      (: :)
      (NP
        (NP
          (NP
            (NP (JJ Proliferating) (NN cell) (JJ nuclear) (NN antigen))
            (PRN (-LRB- -LRB-)
              (NP (NN PCNA))
              (-RRB- -RRB-)))
          (NN expression))
        (PP (IN in)
          (NP (VBN cultured) (JJ human) (NN THP-1) (NN cell) (NN line))))
      (. .))))

(
  (S
    (S
      (LST (-LRB- -LRB-) (LS a) (-RRB- -RRB-))
      (S
        (VP (VBG Proliferating)
          (NP
            (NP
              (NP
                (NP (NN cell) (JJ nuclear) (NN antigen))
                (PRN (-LRB- -LRB-)
                  (NP (NN PCNA))
                  (-RRB- -RRB-)))
              (NN expression))
            (PP (IN in)
              (NP (DT the) (VBN cultured) (JJ human) (NN THP-1) (NN cell) (NN line))))
          (PP (IN after)
            (NP (JJ hormonal) (NN treatment))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Results))
      (VP (VBP are)
        (VP (VBN expressed)
          (PP (IN as)
            (NP
              (NP (DT the) (NN mean) (CD ±) (JJ standard) (NN deviation))
              (PP (IN of)
                (NP
                  (NP (DT the) (NN percentage))
                  (PP (IN of)
                    (NP
                      (NP
                        (NP (NN staining) (NN area))
                        (PRN (-LRB- -LRB-)
                          (NP
                            (NP (JJ positive) (NN area))
                            (VP (VBN defined)
                              (PP (IN as)
                                (NP
                                  (NP (DT the) (NN number))
                                  (PP (IN of)
                                    (NP
                                      (NP (NNS pixels))
                                      (ADJP (JJ detectable)
                                        (PP (IN per)
                                          (NP (NN micron) (NN square))))))))))
                          (-RRB- -RRB-)))
                      (PP (IN for)
                        (NP
                          (NP (CD 100) (NNS cells))
                          (PP (IN in)
                            (NP (CD five) (JJ different) (NNS experiments))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN Bottom))
      (: :)
      (NP (NN western) (NN blot) (NN analysis)))
    (. .)))

(
  (S
    (S
      (LST (-LRB- -LRB-) (LS b) (-RRB- -RRB-))
      (NP (NN PCNA))
      (VP (NN expression)
        (PP (IN in)
          (NP
            (NP (JJ untreated) (NN THP-1) (NNS cells))
            (PRN (-LRB- -LRB-)
              (NP (JJ control) (JJ -LSB-cnt))
              (-RRB- -RSB-) (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (LST (-LRB- -LRB-) (LS c) (-RRB- -RRB-))
      (NP
        (NP (NN PCNA) (NN expression))
        (PP (IN in)
          (NP (NN THP-1) (NNS cells))))
      (VP (VBN treated)
        (PP (IN with)
          (NP
            (NP (NN testosterone))
            (PRN (-LRB- -LRB-)
              (NP (NN T))
              (-RRB- -RRB-))))
        (PP (IN after)
          (NP (CD 168) (NNS hours)))))
    (. .)))

(
  (S
    (S
      (LST (-LRB- -LRB-) (LS d) (-RRB- -RRB-))
      (NP
        (NP (NN PCNA) (NN expression))
        (PP (IN in)
          (NP (NN THP-1) (NNS cells))))
      (VP (VBN treated)
        (PP (IN with)
          (NP
            (NP (NN 17β-oestradiol))
            (PRN (-LRB- -LRB-)
              (NP (NN E2))
              (-RRB- -RRB-))))
        (PP (IN after)
          (NP
            (NP (CD 168) (NNS hours))
            (PRN (-LRB- -LRB-)
              (NP
                (NP (NN magnification))
                (, ,)
                (NP (NN ×) (CD 500)))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (NP (NN Figure) (CD 3))
      (: :)
      (NP
        (NP (NN Apoptosis) (NN evaluation))
        (PP (IN in)
          (NP (VBN cultured) (JJ human) (NN THP-1) (NN cell) (NN line)))))
    (. .)))

(
  (S
    (S
      (LST (-LRB- -LRB-) (LS a) (-RRB- -RRB-))
      (NP (NN Apoptosis))
      (VP (NN evaluation)
        (PP (IN in)
          (NP (DT the) (VBN cultured) (JJ human) (NN THP-1) (NN cell) (NN line)))
        (PP (IN after)
          (NP
            (NP (CD 168) (NNS hours))
            (PP (IN of)
              (NP
                (NP (JJ hormonal) (NN treatment))
                (PP
                  (PP (IN without))
                  (CC and)
                  (PP (IN with)
                    (NP (NN staurosporine))))))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Results))
      (VP (VBP are)
        (VP (VBN expressed)
          (PP (IN as)
            (NP
              (NP (DT the) (NN mean) (NN ±) (JJ standard) (NN deviation))
              (PP (IN of)
                (NP
                  (NP (DT the) (NN percentage) (NN number))
                  (PP (IN of)
                    (NP (JJ annexin-positive) (NNS cells)))))
              (PP (IN in)
                (NP (CD five) (JJ different) (NNS experiments))))))))
    (. .)))

(
  (S
    (S
      (LST (-LRB- -LRB-) (LS b) (-RRB- -RRB-))
      (NP
        (NP (JJ Apoptotic) (NN DNA) (NN evaluation))
        (PP (IN in)
          (NP (NN THP-1) (NNS cells)))
        (PP (IN after)
          (NP
            (NP (CD 168) (NNS hours))
            (PP (IN of)
              (NP
                (NP (JJ hormonal) (NN treatment))
                (PP (IN without)
                  (NP (NN staurosporine))))))))
      (ADVP (RB as))
      (VP (VBN detected)
        (PP (IN by)
          (NP (NN flow) (NN analysis) (NN cytometry) (NN scatter) (NN analysis)))))
    (. .)))

(
  (S
    (NP
      (NP
        (NP
          (NP (NN Region) (NN G))
          (, ,)
          (NP (NN control)))
        (PRN (-LRB- -LRB-)
          (NP (NN cnt))
          (-RRB- -RRB-)))
      (, ,)
      (NP
        (NP (CD 3.96) (NN %))
        (: ;)
        (NP
          (NP (NN 17β-oestradiol))
          (PRN (-LRB- -LRB-)
            (NP (NN E2))
            (-RRB- -RRB-)))
        (, ,)
        (NP (CD 5.54) (NN %))
        (: ;)
        (NP
          (NP (NN testosterone))
          (PRN (-LRB- -LRB-)
            (NP (NN T))
            (-RRB- -RRB-)))
        (, ,)
        (NP (CD 15.9) (NN %)))
      (. .))))

(
  (S
    (NP
      (NP
        (LST (-LRB- -LRB-) (LS c) (-RRB- -RRB-))
        (JJ Apoptotic) (NN DNA) (NN evaluation))
      (PP (IN in)
        (NP (NN THP-1) (NNS cells)))
      (PP (IN after)
        (NP
          (NP (CD 168) (NNS hours))
          (PP (IN of)
            (NP
              (NP (JJ hormonal) (NN treatment))
              (CC and)
              (NP
                (NP
                  (NP (NN staurosporine))
                  (PRN (-LRB- -LRB-)
                    (NP (NN stau))
                    (-RRB- -RRB-)))
                (PP (IN for)
                  (NP (CD 24) (NNS hours))))))
          (, ,)
          (SBAR (IN as)
            (S
              (VP (VBN detected)
                (PP (IN by)
                  (NP (NN flow) (NN analysis) (NN cytometry) (NN scatter) (NN analysis))))))))
      (. .))))

(
  (S
    (NP
      (NP (NN Region) (NN G))
      (: :)
      (NP
        (NP (NN control/S))
        (, ,)
        (NP
          (NP (CD 18.9) (NN %))
          (: ;)
          (NP (NN E2/S))
          (, ,)
          (NP (CD 16.5) (NN %))
          (: ;)
          (NP (NN T/S))
          (, ,)
          (NP (CD 24.5) (NN %))))
      (. .))))

(
  (S
    (NP
      (NP (NN PI))
      (, ,)
      (NP (NN propidium) (NN iodide))
      (. .))))

(
  (S
    (S
      (NP
        (NP (NN Figure) (CD 4))
        (: :)
        (NP
          (NP (NN Poly-ADP-ribose) (NN polymerase))
          (PRN (-LRB- -LRB-)
            (NP (NN PARP))
            (-RRB- -RRB-))))
      (VP (VBD -cleaved)
        (NP
          (NP (NN expression))
          (PP (IN in)
            (NP (VBN cultured) (JJ human) (NN THP-1) (NN cell) (NN line))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (LST (-LRB- -LRB-) (LS a) (-RRB- -RRB-))
          (NN Poly-ADP-ribose) (NN polymerase))
        (PRN (-LRB- -LRB-)
          (NP (NN PARP))
          (-RRB- -RRB-)))
      (NP
        (NP (JJ -cleaved) (NN expression))
        (PP (IN in)
          (NP (DT the) (VBN cultured) (JJ human) (NN THP-1) (NN cell) (NN line)))
        (PP
          (PP (IN in)
            (NP (JJ basal) (NNS conditions)))
          (CC and)
          (PP (IN after)
            (NP
              (NP (CD 168) (NNS hours))
              (PP (IN of)
                (NP
                  (NP (JJ hormonal) (NN treatment))
                  (CC and)
                  (NP
                    (NP (NN staurosporine))
                    (PRN (-LRB- -LRB-)
                      (NP (NN stau))
                      (-RRB- -RRB-))))))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Results))
      (VP (VBP are)
        (VP (VBN expressed)
          (PP (IN as)
            (NP
              (NP (DT the) (NN mean) (NN ±) (JJ standard) (NN deviation))
              (PP (IN of)
                (NP
                  (NP (DT the) (NN percentage))
                  (PP (IN of)
                    (NP (DT the) (JJ positive) (NN area)))))
              (PP (IN for)
                (NP
                  (NP (CD 100) (NNS cells))
                  (PP (IN in)
                    (NP (CD five) (JJ different) (NNS experiments))))))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Bottom))
      (: :)
      (NP
        (NP (NN western) (NN blot) (NN analysis))
        (ADJP (JJ related)
          (PP (TO to)
            (NP
              (NP (JJ PARP-cleaved) (NN expression))
              (PP (IN in)
                (NP
                  (NP
                    (NP (JJ untreated) (NNS cells))
                    (PRN (-LRB- -LRB-)
                      (NP (JJ basal) (NN condition))
                      (-RRB- -RRB-)))
                  (CC and)
                  (NP
                    (NP (NNS cells))
                    (VP (VBN treated)
                      (PP (IN with)
                        (NP
                          (NP (NNS hormones))
                          (CC and)
                          (NP (NN staurosporine))))))))))))
      (. .))))

(
  (S
    (S
      (LST (-LRB- -LRB-) (LS b) (-RRB- -RRB-))
      (VP (VBD PARP-cleaved)
        (NP
          (NP (NN expression))
          (PP (IN in)
            (NP (NN THP-1) (NNS cells))))
        (PRN (-LRB- -LRB-)
          (NP (JJ basal) (NN condition))
          (-RRB- -RRB-))))
    (. .)))

(
  (S
    (S
      (LST (-LRB- -LRB-) (LS c) (-RRB- -RRB-))
      (VP (VBD PARP-cleaved)
        (NP
          (NP (NN expression))
          (PP (IN in)
            (NP (NN THP-1) (NNS cells))))
        (PP (IN after)
          (NP (JJ normal) (NN medium)))))
    (. .)))

(
  (S
    (S
      (LST (-LRB- -LRB-) (LS d) (-RRB- -RRB-))
      (VP (VBD PARP-cleaved)
        (NP
          (NP (NN expression))
          (PP (IN in)
            (NP (NN THP-1) (NNS cells))))
        (PP (IN after)
          (NP
            (NP
              (NP (NN testosterone))
              (PRN (-LRB- -LRB-)
                (NP (NN T))
                (-RRB- -RRB-)))
            (NN treatment)))))
    (. .)))

(
  (S
    (S
      (PRN (-LRB- -LRB-)
        (NP (NN e))
        (-RRB- -RRB-))
      (VP (VBD PARP-cleaved)
        (NP
          (NP (NN expression))
          (PP (IN in)
            (NP (NN THP-1) (NNS cells))))
        (PP (IN after)
          (NP (NN 17β-oestradiol) (-LRB- -LRB-) (NN E2) (-RRB- -RRB-) (NN treatment)))))
    (. .)))

(
  (S
    (NP
      (NP (NN cnt))
      (, ,)
      (NP (NN control))
      (. .))))

(
  (S
    (NP
      (NP (NN Figure) (CD 5))
      (: :)
      (NP
        (NP
          (NP
            (NP
              (NP (JJ NF-κB) (NN p65))
              (, ,)
              (NP (NN IκB-α))
              (CC and)
              (NP (JJ phosphorylated) (NN IκB-α)))
            (PRN (-LRB- -LRB-)
              (NP (NN ser) (CD 32))
              (-RRB- -RRB-)))
          (NN protein) (NN expression))
        (PP (IN in)
          (NP (DT the) (VBN cultured) (JJ human) (NN THP-1) (NN cell) (NN line)))
        (PP (IN after)
          (NP
            (NP (CD 168) (NNS hours))
            (PP (IN of)
              (NP
                (NP (JJ hormonal) (NN treatment))
                (PP (IN without)
                  (CC or)
                  (PP (IN with)
                    (NP (NN staurosporine)))))))))
      (. .))))

(
  (S
    (S
      (NP (DT The) (NNS results))
      (VP (VBP are)
        (ADJP (JJ representative)
          (PP (IN of)
            (NP (CD four) (JJ separate) (NNS experiments))))))
    (. .)))

(
  (S
    (S
      (PRN
        (NP (NN CNT))
        (, ,)
        (NP (NN control))
        (: ;)
        (NP (NN T))
        (, ,)
        (NP (NN testosterone))
        (: ;)
        (NP (NN E2))
        (, ,)
        (NP (NN 17β-oestradiol))))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure) (CD 6))
      (: :)
      (NP
        (NP (JJ Electrophoretic) (NN mobility) (NN shift) (NN assay))
        (PP (IN for)
          (NP
            (NP (NN NF-κB))
            (PRN (-LRB- -LRB-)
              (NP (NN arrow))
              (-RRB- -RRB-))))
        (PP (IN in)
          (NP (DT the) (VBN cultured) (JJ human) (NN THP-1) (NN cell) (NN line))))
      (. .))))

(
  (S
    (NP
      (NP
        (LST (-LRB- -LRB-) (LS a) (-RRB- -RRB-))
        (JJ Electrophoretic) (NN mobility) (NN shift) (NN assay))
      (PP (IN for)
        (NP
          (NP
            (NP (NN NF-κB))
            (PRN (-LRB- -LRB-)
              (NP (NN arrow))
              (-RRB- -RRB-)))
          (PP (IN in)
            (NP (DT the) (VBN cultured) (JJ human) (NN THP-1) (NN cell) (NN line)))))
      (PP
        (PP (IN after)
          (NP
            (NP (CD 168) (NNS hours))
            (PP (IN of)
              (NP (JJ hormonal) (NN treatment)))))
        (CC and)
        (PP (IN without)
          (CC or)
          (PP (IN with)
            (NP
              (NP (NN staurosporine))
              (PRN (-LRB- -LRB-)
                (NP (CD 17) (NN nM))
                (-RRB- -RRB-)))))))
    (VP (VBZ reveals)
      (NP
        (NP (DT an) (VBN increased) (NN DNA) (NN binding))
        (PP (IN in)
          (NP
            (ADJP (NN 17β-oestradiol) (-LRB- -LRB-) (NN E2) (-RRB- -RRB-) (JJ -treated))
            (NNS cells)))))
    (. .)))

(
  (S
    (S
      (LST (-LRB- -LRB-) (LS b) (-RRB- -RRB-))
      (NP
        (NP (NN Super) (NN shift) (NN assay))
        (PP (IN for)
          (NP
            (NP
              (NP (NN p65))
              (PRN (-LRB- -LRB-)
                (NP (NN arrow))
                (-RRB- -RRB-)))
            (PP (IN in)
              (NP
                (NP (DT the) (NNS cells))
                (PP (IN under)
                  (NP (DT the) (JJ same) (NNS conditions))))))))
      (VP (VBZ confirms)
        (NP
          (NP (DT the) (VBN increased) (NN binding))
          (PP (IN of)
            (NP (NN p65)))
          (PP (IN in)
            (NP (JJ E2-treated) (NNS cells))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NNS results))
      (VP (VBP are)
        (ADJP (JJ representative)
          (PP (IN of)
            (NP (CD four) (JJ separate) (NNS experiments))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN cnt))
        (, ,)
        (NP (NN control) (: ;) (NN T))
        (, ,))
      (NP (NN testosterone)))
    (. .)))

(
  (S
    (NP
      (NP (NN Table) (CD 1))
      (: :)
      (NP
        (NP
          (NP (NN NF-κB) (NN complex))
          (, ,)
          (NP (NN IκB-α))
          (CC and)
          (NP (NN IκB-α-ser) (CD 32)))
        (VP (VBN evaluated)
          (PP (IN by)
            (NP (NN immunocytochemistry))))))))

